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Abstract 
Brain Derived Neurotrophic Factor (BDNF), a member of the family of 
neurotrophins, is a key molecule involved in growth, development and 
modulation of the neuronal system. Due to its critical role in a large number of 
neuronal processes, BDNF altered functions and levels are associated strongly 
with many different neuropsychiatric disorders. Since quantification of PreBDNF, 
ProBDNF and Mature BDNF in human serum is considered a promising 
biomarker of neuropsychiatric diseases, the possibility to further differentiate 
between BDNF isoforms appears particular attractive in order to develop novel 
and more accurate tools for compound screening, as well as for the diagnosis 
and the follow-up of medical treatment of these disorders. In this Ph.D. study, a 
method for the purification of antibodies directly towards BDNF isoform 
precursors and Mature form was developed, and the specific purified antibodies 
were utilized in immunochemical assays, in order to study the trafficking of 
BDNF in neuronal cells. 
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1. Introduction 
1.1 Protein purification: a brief history 
In 1901 Hermann Emil Fischer synthesised a dipeptide, demonstrating that 
aminoacids can be linked together, and the following year Franz Hofmeister 
suggested that proteins are aminoacids linked by peptide bonds. Many years 
later, in 1926, James B. Sumner crystallised the enzyme urease and showed by 
chemical analysis that the substance was a protein. Linus Pauling and co-workers 
proposed in 1951 that the primary structural motifs of proteins are α-helices and 
β-sheets. Anfinsen later suggested that the native structure of a protein is the 
thermodynamically most stable structure with the given aminoacid sequence. 
Protein purification has been developed in parallel with the discovery and 
further studies of proteins. Protein purification has been performed for more 
than 200 years, but until the beginning of the 20th century, the only available 
separation technologies were methods such as filtration, precipitation, and 
crystallisation.  
In 1903 the botanist Mikhail Tswett described his work on separation of plant 
pigments on a column of calcium carbonate. Later, in 1906, he introduced the 
term chromatography. During the next several decades, other important protein 
separation methods were developed: electrophoresis1,2 and affinity 
chromatography (AC) in the 1930s and ion exchange chromatography (IEX) in the 
1940s. Hydroxyapatite, which can be regarded as a mixed-mode ion exchanger, 
was developed in 1956 by Arne Tiselius and co-workers. 
                                                          
1 Kolin; Proc. Natl. Acad. Sci. USA, 1955, 41: 101 
2 Shapiro et al.; Biochem. Biophys. Res. Commun, 1967, 28: 815 
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During the 1950s and 1960s several new hydrophilic chromatography matrices 
were developed3. The matrices are the solid porous material to which functional 
groups (ligands) are coupled to obtain a chromatography medium. In 1955, 
starch was used to separate proteins based on differences in size4,5. In 1959, 
Jerker Porath, Per Flodin and Bjorn Ingelman developed cross-linked dextran, 
which was more suitable for this purpose. During the 1960s other hydrophilic 
materials for electrophoresis and chromatography where developed: 
polyacrylamide, methacrylate, porous silica, and agarose.  
The introduction of cyanogen bromide activation by Rolf Axen and co-workers 
(1967) allowed ligand coupling to polysaccharides such as in agarose6,7. This 
discovery is the foundation of the modern affinity chromatography media. 
Affinity chromatography, as it is known today, was introduced in 1968 by Pedro 
Cuatrecasas, Chris Anfinsen and Meir Wilchek8. In the 1960s and 1970s reversed 
phase chromatography (RPC)9, hydrophobic interaction chromatography (HIC)10, 
and immobilised metal ion affinity chromatography (IMAC)11 were developed 
and during the 1970s and 1980s a large number of chromatography media 
became available on the market. During the 1980s and 1990s affinity 
tagging12,13,14 of proteins became popular and it allowed efficient purification. 
Because the same affinity tag could be used on many different proteins, generic 
                                                          
3
 Albertsson; Partitioning in aqueous two-phase systems, Academic Press, Inc., 1985 
4
 Lindqvist, Storgards; Nature, Lond., 1955, 175: 511 
5
 Lathe, Ruthven; Biochem. J., 1956, 62: 665 
6
 Axén, Porath, Ernback; Nature, 1967, 214: 1302 
7
 Porath, Axén, Ernback; Nature, 1967, 215: 1491 
8
 Cuatrecasas, Wilchek, Anfinsen; Proc. Natl. Acad. Sci. USA, 1968, 61: 636 
9
 Hancock, Bishop, Prestidige, Hardling, Hearn; J. Chromatogr., 1978, 153:391 
10
Amersham Biosciences; Hydrophobic Interaction Chromatography – Principles and 
methods; 2000 
11
 Porath, Carlsson, Olsson, Belfrage; Nature, 1975, 258: 598 
12
 Li, Wang, Guo, Shi, Wang, Chen, Zheng; Sep. Sci. Technol, 2011, 46: 309 
13
Todorova, Vijayalekshmi; Immobilized metal-ion affinity chromatography, in: Hage; 
Handbook of Affinity Chromatography, 2
nd
 ed., CRC Press, Boca Raton, 2005 
14
 Gutierrez, Martin del Valle, Galan; Sep. Purif. Rev., 2007, 36: 71 
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and time-saving purification protocols could be developed. During this time, 
most purifications were undertaken starting with natural sources, where 
extremely low concentration of target protein in the source organisms often 
made purification of even a few micrograms difficult and time consuming. 
Protein purification is now performed in scales from micrograms and milligrams 
in research laboratories to kilograms and tonnes in industrial settings. 
Sometimes proteins are purified in parallel, using automated chromatography 
systems. The efficiency gained by the generic purification approaches based on 
affinity tagging of the target protein has revolutionised protein purification, and 
today many proteins can be purified very easily and efficiently. However these 
methods do not always provide sufficient purity, and if  high purity standards are 
requested, it should be noted that additional physicochemical-based 
chromatography methods, for example, size exclusion (SEC), IEX15, and HIC may 
thus have to be added to the protocol.  
Despite the successes achieved, the purification “paradigm” still moves interests 
and efforts in the continuous demand for improved separation performances16. 
  
                                                          
15
 Amersham Biosciences; Ion Exchange Chromatography & Chromatofocusing – 
Principles and methods; 2004 
16
 Roque, Silva, Taipa; J. Chrom. A, 2007, 1160: 44 
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1.2 General concepts of protein purification 
In the last 50 years the demand of efficient and safe biopharmaceuticals has 
dramatically increased. A biopharmaceutical could be a compound with a proper 
biological activity, a molecule suitable for the conjugation with pharmaceutical 
compound, small therapeutic peptides or a molecule for the detection of specific 
target17.  
The key point is: biopharmaceuticals derive from biological sources and 
especially from a biotechnology process18. Due to their origin, they are usually 
produced in vivo or by using recombinant technologies via fermentation, and for 
their application, they are subject to strict criteria of purity.  
The downstream process consists of recovery steps that isolate the target 
product from the production system and purification steps that remove all 
impurities to an acceptable level. The type and sequence of steps depend on the 
target molecule and the production organism. The most common methods for 
preparative purification of proteins all involve chromatography19. The separation 
methods are based on the differences between the properties of the protein to 
be purified (the target protein) and the properties of other substances in the 
sample (Figure 1.1). 
                                                          
17
 Scott, Musgrave; Chem. Today, 2011, 29, 4 
18
 http://www.merriam-webster.com/dictionary 
19
 DePalma; GEN, 2005, 25,18: 50 
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 SEC  HIC  IEX  AC  RPC 
 
Figure 1.1: different purification methods. SEC: Size exclusion chromatography, HIC: 
Hydrophobic interaction chromatography, IEX: ion exchange chromatography
20
, AC: 
affinity chromatography, RPC: reversed phase chromatography. 
After a first recovery process of the target molecule form the source of 
production, it is possible to start the purification process with a clarified, 
particle-free intermediate mixture. All the chromatographic methods are based 
on reversible interactions between a protein and a specific ligand coupled to the 
matrix. A “bind-elute” approach, where the target molecule interacts with the 
media and its recovery occurs during the elution stage, is usually preferred to the 
“flow-through” approach, where the contaminants are retained through the 
column and the target molecule is purified as unbound material. 
There are four principal elution mechanisms: the first (number 1 in Figure 1.2) is 
the simplest case where, by changing the buffer composition, the elution of the 
bound substance occurs without modification of neither the target molecule nor 
the ligand. In the second situation (number 2 in Figure 1.2), permanent or 
temporary damages occur both for the purified substance and the ligand 
because extreme high pH or chaotropic agents are required for the elution. The 
last two methods (number 3 and 4 in Figure 1.2) are based on the specific elution 
by addition of a substance that competes for binding. 
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Figure 1.2: Elution methods. 
The key point of a purification process design is the selection of the method and 
of all raw materials for the development of the most appropriate sequence of 
steps in order to satisfy crucial objectives like high purity, high recovery and high 
capacity, leading to high productivity. The building blocks commonly used for 
chromatography are based upon the separation by size (SEC), charge (IEX), 
hydrophobicity (HIC), lipophilicity (RPC) and bio-recognition (AC). The 
discrimination power increases in the following order: SEC<IEX, HIC, RPC<AC. But 
if an affinity purification step is introduced in the first step of the purification 
chain, the number of successive operation can be reduced21,22. 
Crucial parameters during a purification process are: purity, recovery, capacity 
and the resultant productivity. High purity is achieved by a high-selectivity 
chromatography resin. This type of support allows an efficient separation 
between the target and the impurities and the recovery of a non-denatured 
product. Also the capacity of a matrix, in particular the dynamic binding capacity 
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22
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(DBC), is important for the set-up of the chromatographic process. The DBC is 
the maximum amount of material that can be adsorbed by the resin before 
material leaks through the bed under determined conditions (running 
conditions, pH, ionic strength, concentration of interfering substances)23,24. The 
productivity, finally, is dependent on the previous parameters and can be 
summarised as: 
 
1.2.1 The CIPP concept: Cleaning, Intermediate Purification, 
Polishing 
The design of a purification process is usually based on the three different stages 
of the CIPP: capture, intermediate purification and polishing. This approach, 
together with a rational pre-selection of raw materials, enables to achieve the 
most cost efficient and robust production of the target substance. In addition, in 
this way it is possible to monitor the optimisation and eventual troubleshooting 
in order for a process validation. Generally, the first stage of the process 
development concerns the investigation about the property of different resins. 
Dynamic binding capacity is determined and the conditions of each step of the 
purification are optimised in terms of loading conditions (pH, conductivity, 
concentration, etc.) buffers, flow rates, regeneration, sanitisation etc. in order to 
have at the end a compromise between capacity, purity and the time required 
for each step. 
                                                          
23
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Figure 1.3: CIPP concept scheme. 
 
 
Capture stage 
This is the first step to isolate the target 
substance from the bulk of the impurities like 
proteases, DNA, culture media components, 
cellular debris etc. During the first capture 
step it is possible to have a several fold 
reduction in volume which results in a 
significant time and cost savings for the 
further downstream. During the choice of the best chromatographic technique 
the best compromise between cost and performance are considered. Affinity 
chromatography and ion exchange chromatography are widely used for this 
purpose.  
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Intermediate purification stage 
It is the intermediate purification step, where 
remaining impurities such Host Cell Protein 
(HCP) and DNA or process related impurities 
are removed. This step may also provide viral 
clearance, if needed. Sometimes the product, 
after the capture step, is so pure that it is 
possible to skip the purification step and go 
directly to the polishing step (this is very frequent in purification processes 
where Protein-A affinity is used). Ion exchange or hydrophobic interaction are 
typically utilised for this intermediate step and frequently a “flow-through” 
approach is preferred to the “bind-elute” approach. Flow-through steps offer the 
advantage of increased capacity to process the target product, especially when 
impurities are only present in low concentrations. 
 
Polishing stage 
Polishing stage is generally used to remove 
traces of impurities or modified target 
molecules in the final product. At this stage a 
high degree of resolution is required and ion 
exchange, hydrophobic interaction, ceramic 
hydroxyl apatite, and multi-modal 
chromatography are the used techniques25. 
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1.3 Affinity chromatography 
Affinity chromatography separates proteins on the basis of a reversible 
interaction between a protein (or group of proteins) and a specific ligand 
coupled to a chromatography matrix26. The technique is ideal for a capture or 
intermediate step in a purification protocol and can be used whenever a suitable 
ligand is available for the protein of interest.  
Thanks to high selectivity, high resolution, and high capacity for the protein of 
interest, purification levels in the order of several thousand-fold with high 
recovery of active material are achievable. Affinity chromatography is unique in 
purification technology since it is the only technique that enables the purification 
of a biomolecule on the basis of its biological function or individual chemical 
structure8,27. Biological interactions between ligand and target molecule can be a 
result of electrostatic or hydrophobic interactions, van der Waals' forces and/or 
hydrogen bonding. To elute the target molecule from the affinity medium the 
interaction can be reversed, either specifically using a competitive ligand, or 
non-specifically, by changing the pH, ionic strength or polarity. 
 
 
Figure 1.4: Scheme of a AC purification process. 
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Figure 1.5: Typical chromatogram in affinity purification. 
 
Purification that would otherwise be time-consuming, difficult or even 
impossible using other techniques can often be easily achieved by introducing an 
affinity purification step in the purification sequence: in this way the number of 
successive operations can be reduced21,22 and the target protein is collected in a 
purified, concentrated form. In a single step, affinity purification can offer 
immense time-saving over less selective multistep procedures, enabling the 
processing of large volumes. Target molecules can be purified from complex 
biological mixtures, native forms can be separated from denatured forms of the 
same substance and small amounts of biological material can be purified from 
high levels of contaminating substances.  
Successful affinity purification requires a biospecific ligand that has to be 
covalently attached to a chromatography matrix. The coupled ligand must retain 
its specific binding affinity for the target molecules, and after washing away 
unbound material, the binding between the ligand and target molecule must be 
reversible to allow the target molecules to be removed in an active form. Any 
component can be used as a ligand to purify its respective binding partner. The 
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interaction can be biospecific, for example enzyme-substrate28, enzyme-
inhibitor, enzyme-cofactor29, antibodies-Protein-A, antibody-antigen, antibody-
cell, nucleic acid-complementary base sequence, receptor-hormone, or non-
biospecific, for example, a protein binding a dye substance30, affinity tagged 
proteins or histidine-containing proteins binding metal ions31,32. 
The high selectivity of affinity chromatography enables many separations to be 
achieved in one or two simple steps33, including, for example, common 
operations such as the purification of monoclonal antibodies or fusion proteins 
from the cell culture supernatant. It is, however, more common for affinity 
chromatography to be used as the first capture step, to obtain a concentration 
of the sample, followed by a polishing step to remove remaining impurities or 
aggregates.   
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1.4 Antibody purification 
1.4.1 Purification of Immunoglobulins G 
Nowadays the success of antibodies34 in therapy and in the research field, has 
addressed the efforts of the industries to large scale antibody production35. The 
majority of them are produced by recombinant technology or hybridomas. Most 
products are whole antibodies and some are antibody fragments. The 
production in mammalian cells has been improved in recent years and at the 
moment a modern cell culture process can achieve an antibody concentration 
exceeding 5 g/L 36. 
The problem in the administration in vivo of antibodies is the contamination of 
the final product by DNA, viruses, pyrogens and leachates either from the 
production or from the separation media. Downstream processing is the key 
point for the development of biotherapeutics because it covers between 50-80% 
of the total manufacturing costs37. Purification processes need to target the 
highest purity product, the highest yield combined to the minimum costs 
associated with loss of product. Traditionally the purification process involves an 
initial enrichment (by removing of water, precipitation with ammonium sulfate, 
with filtration techniques), a rough cleaning of main contaminants, an 
intermediary purification in which a 40-90% of the final purity is achieved and a 
final purification to obtain a purity close to 100%
16,38,39. 
There are a wide pool of bioengineered and synthetic ligands generated by the 
rational, the combinatorial and the combined methods that have high specificity 
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and selectivity40,41. They represent great alternatives to traditional biospecific 
ligands like Protein-A. Also if the research of industries and academia is 
addressed to new synthetic mimic ligands42,43,44,45, the most widely used affinity 
system for the purification of antibodies is still based on the use of Protein-A. 
Over the years, it has shown to have high selectivity, resulting in >95% purity in a 
single step starting from complex cell culture media46. This protein recognises 
selectively IgG1, IgG2 and IgG4 subclasses
47,48. Another affinity ligand originating 
from a bacterial species is the Streptococcal Protein-G, the first choice for the 
purification of IgG3 subclass. Due to its stability and the wide recognition for the 
majority of the IgG subclasses, Protein-A is preferred to Protein-G. Recombinant 
forms and synthetic ligands that mime the Protein-A activity have also been 
developed49,50,51. 
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Figure 1.6: Basic antibody (IgG) structure
61
.  
Wild type Protein-A is a 42 kDa cell wall associated protein domain exposed on 
the surface of the Gram-positive bacterium Staphylococcus aureus. It has a high 
affinity to the Fc part of IgG from various species (human, rabbit, guinea pig, 
weak interactions with bovine and mouse). 
The wild type Protein-A consists of three different regions: 
 The signal sequence processed during the secretion 
 The “binding region”, formed by five homologous IgG binding domain 
 The cell-wall anchoring region.  
The domains are independently capable to bind strongly to the Fc-part of IgG1, 
IgG2 and IgG4 but show weak interaction with IgG3
52. 
Immobilisation of Protein-A can be done via different chemistries most 
frequently via thiol or epoxy groups. A non-oriented immobilisation may provide 
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a multiple attaching53 points that could be beneficial for the ligand stability as 
well as minimisation of ligand leakage. The disadvantage of this approach is that 
multiple attaching points may interfere with the functional regions of the 
protein54. The capacity of the resin is dependent on ligand density, but steric 
effects will also play a role. In addition the amount of the recovered antibody is 
closely dependent on the orientation of the ligand55.  
Ligands are essential components in affinity chromatography, as they play a 
major role in specificity and stability of the system. The general characteristics 
that need to be considered are the affinity to the target, its specificity, the 
immobilisation feasibility, the stability in harsh washing and elution conditions 
and the retention of target binding capacity after the attachment to the matrix. 
It is often necessary to modulate the peptide density56 and orientation to avoid 
steric hindrance of the binding sites in order to achieve maximum binding. In 
many cases the use of a spacer arm for the attachment of ligand to the matrix 
may be crucial to avoid these problems, and the length and nature of spacer 
should be considered28,32,57. To ensure a correct interaction between antigen and 
antibodies, the orientation of the ligand during the immobilisation of the peptide 
and the resin has to be considered58 exploiting, for instance, the different 
reactivity of the chemical groups on the molecule to be coupled in ways to 
obtain an oriented attachment. Some commercial products, as well the Sulfolink 
coupling resin, exploit a derivatization of the matrix with a spacer arm and a 
iodoacetyl group that reacts specifically with free sulfhydryls at pH 7.5- 959. By 
means the same principle based on the different reactivity of the different 
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chemical group, it is possible to address the coupling on an epoxy matrix by 
introducing a thiol group (Cysteine) in the C-terminal position of the antigen. 
Many matrices manufactured for lab scale and process chromatography, based 
on wild type and recombinant Protein-A, are commercially available52. Until few 
years ago, before the launch on the market of recombinant Protein-A based 
products like Mab Select (high capacity recombinant Protein-A based matrix), 
one of the most largely employed supports for antibody purification was the 
nProtein-A Sepharose® 4 Fast Flow. 
nProtein-A Sepharose® 4 Fast Flow is based on wild type Protein-A (nProtein-A) 
immobilised on Sepharose (agarose crosslinked beads) using a cyanogen 
bromide strategy. nProtein-A Sepharose® 4 Fast Flow has high chemical, 
mechanical and thermal stability and it contains approximately 6 mg of nProtein-
A per ml of drained gel. The total binding capacity for human IgG is 
approximately 35 mg/ml60. 
 
1.4.2 Purification of antibodies directed towards specific antigens 
With the growing competition in the development of antibody-based products, 
there is extensive pressure on the industry to develop high affinity reagents and 
strategies to meet the demand-supply expectation, along with rapid and 
economical procedures to obtain high quality products. Advances in antibody 
engineering has facilitated the generation of high affinity reagents and has 
shifted the focus towards the downstream processes for the production of 
antibodies. The last two decades have witnessed significant advantages in 
purification strategies using affinity chromatography, partially as a result of 
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development in the preparation of many affinity resins for the specific 
purification of antibodies61,62. 
Site-specific, high affinity polyclonal antibodies are effectively and successfully 
produced by immunising rabbits with synthetic peptides. The use of these 
molecules in immunochemical analysis is often limited because of non-specific 
binding with a subsequent low purity63. 
Antigen-specific antibodies can be obtained by immobilising a specific antigen on 
the chromatographic support and using them for isolating specific antibodies 
from a complex mixture64. Whole antigens or specific peptides, representing 
antigenic epitope(s), can be used for this purpose. However, such a method may 
lead to the selection of antibodies with different affinities, in particular in a 
polyclonal population, which will require further optimisation of elution 
conditions based on the affinity of the antibodies to purify65,66,67. 
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1.5 Research application of purified antibodies: the BDNF-study 
1.5.1 The Neurotrophins 
In the 1950s Levi-Montalcini and Hamburger68 discovered soluble factors 
inducing the hypertrophy and fiber outgrowth of sympathetic neurons. Later it 
was identified as Nerve Growth Factor (NGF)69,70,71. Twenty years later, another 
neurotrophic factor, highly homologous to NGF72,73, was identified: the Brain-
derived Neurotrophic Factor (BDNF). BDNF and NGF are both members of the 
neurotrophin family consisting of small secreted proteins that play an important 
roles in the development of the nervous system in vertebrates74,75,76. Since then, 
four additional members of the family of neurotrophins have been identified 
(neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6) and 
neurotrophin-7 (NT-7)). NT-6 and NT-7 have been found only in fish77,78.  
The road to reach the extracellular space is characterised by some common 
steps. The mRNA is addressed to ER, the synthesised Pro-protein is then packed 
in transport vesicles and finally accumulates in the membrane stacks of the 
trans-Golgi network (TGN). Here, NTs can be sorted to the constitutive pathway, 
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where secretory vesicles are transported by default to cell periphery, or to the 
regulated pathway, dependent upon calcium regulation79 (Figure 1.7). 
 
 
Figure 1.7: Schematic representation of BDNF traffic.  
Once secreted, NTs can bind to two types of cell surface receptors, the Trk 
tyrosine kinases and the p75 neurotrophin receptor (p75NTR)80,81. Each Trk 
receptor (Trk A, Trk B and Trk C) is preferentially activated by one or more NTs 
and is responsible for mediating most cellular responses. More specifically TrkA 
is activated by NGF, TrkB by BDNF and NT-4/5, and TrkC by NT-3 (Figure 1.8). 
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Figure 1.8: NTs binding to their receptor
82
. 
Binding of the NT initiates Trk dimerisation, transphosphorylation of tyrosine 
residues in its cytoplasmic domain and kinase activation (see Figure 1.8). The 
phosphotyrosine residues behave as binding sites for recruiting specific 
cytoplasmic signalling proteins. These proteins may in turn be activated by 
phosphorylation. Contrarily to Trk receptors, p75NTR can be activated by the 
binding with all the four neurotrophins with approximately equal affinity, even if 
it is lower than Trk receptors. While Trk receptors transmit positive signals, 
p75NTR transmits both positive and negative signals. The signals generated by 
the two neurotrophin receptors can either augment or oppose each other, 
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regulating almost all aspects of neuronal development and function, including 
precursor proliferation and commitment, cell survival, axon and dendrite 
growth, membrane trafficking, synapse formation and function, as well as glial 
differentiation and interactions with neurons. Moreover, recent studies have 
revealed a diversity of roles for these factors outside the nervous system, most 
notably in cardiac development, neovascularisation and immune system 
function83,84. 
 
Figure 1.9: diagram of NTs intracellular signalling pathways.  
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1.5.2 Brain-derived Neurotrophic Factor (BDNF)  
1.5.2.1 Distribution and functions  
Brain-derived Neurotrophic Factor, firstly discovered in 1982 by Barde and 
colleagues72, is a member of the family of neurotrophins that is highly conserved 
among several species85,86, is the most studied neurotrophin after Nerve Growth 
Factor and is the most abundant in the brain. BDNF is widely expressed in the 
central nervous system, especially in the hippocampal formation, cerebral 
cortex, and amygdaloid complex87,88,89,90, and its expression increases until 
reaching a maximal level after birth91,92,93,94. Then, the expression of BDNF seems 
not to decline with age95,96,97. However, BDNF is not only widespread distributed 
in the central nervous system, but its mRNA has been observed in numerous 
other tissues as colon, intestine, leukocyte, ovary, spleen, thymus, testis, 
pancreas and blood9899. 
BDNF almost ubiquitary distribution underlines the importance of these 
molecules in a large number of different cellular processes, especially for what 
concerns neuronal functions.  
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In fact this neurotrophin is strongly involved in:  
 cell proliferation100,101,102 
 cell survival/cell death103,104,105 
 differentiation/phenotype maintenance106,107 
 dendrites and axon arborisation108,109 
 spines maturation110,111 
 synapse maturation112,113 
 synaptic transmission114,115 
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1.5.2.2 BDNF gene structure  
All genes encoding neurotrophins have a basically similar structure but among all 
discovered neurotrophins the genomic structure of the BDNF gene is unusually 
complex. Despite the fact that the gene organization and regulation of human 
and rodent BDNF gene expression have received close attention during the last 
decade, knowledge of the structural organization of mouse, rat and human BDNF 
gene has been well characterized only in the last years99,116. Each BDNF 
transcripts is composed by non-coding exons spliced upstream of a common 3’ 
exon that encompasses the whole coding sequence. The detailed 
characterization of the rodents and human BDNF gene has revealed the 
existence of four exon clusters, each of them regulated by different promoters 
located upstream of these alternatively spliced exons. These promoters enable a 
precise regulation of BDNF expression in different cell types or in response to 
different stimuli. 
In detail human BDNF gene spans about 70 kb and encode for 11 exons (Errore. 
L'origine riferimento non è stata trovata.). 
MOUSE AND RAT BDNF GENE  
  
HUMAN GENE  
 
Figure 1.10: Comparison between rodent and human BDNF gene. Each roman number 
represents a different exon, grouped in clusters delimitated by the double vertical dash 
(//). Exons Vh and VIIIh are uniquely present in the human gene. 
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Exons II, III, IV, V, Vh, VI, and VIIIh are untranslated exons and translation of the 
transcripts containing these exons starts from the ATG positioned in exon IX. 
Exons I, VII, and VIII contain in-frame ATG codons that could be used as 
alternative translation start sites, leading to the production of protein variants 
differing for the length of the N-terminus. Two exons, VIII and VIIIh, are rarely 
used and always in combination with exon V as the 5′ exon. Exon IX, which is 
always translated, can undergo to alternative splicing events, generating 
transcripts containing variants of exon IX. These variants are named “a”, “b”, “c” 
and “d” or can result from an arrangement of these regions.  
The biological meaning of this complexity has been extensively investigated by 
the group of Professor Tongiorgi (Laboratory of Molecular and Cellular Neuro-
anatomy of the Department of Life Science - University of Trieste). Tongiorgi and 
colleagues demonstrated that BDNF mRNAs are targeted to the distal dendrites 
(>100 m from the soma) in response to tetanic electrical activity or other 
stimuli as BDNF itself117,118. The dendritic targeting was also demonstrated in vivo 
in animal models of epilepsy119. Interestingly, using in situ hybridization, it was 
noticed that different transcripts seem to have different spatial and temporal 
localization in the various neuronal districts such as soma and proximal or distal 
dendrites120, suggesting the existence of a spatiotemporal code that links 
different splice variants to different localizations and biological functions. In fact 
BDNF mRNAs which are localized in proximal dendrites and cell bodies can shape 
the complexity of dendrites that are emerging directly from the soma, while 
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BDNF variants that are localized in distal dendritic districts are involved in the 
regulation of dendrites in the periphery of the neuron121. 
 
1.5.2.3 BDNF isoform and precursors: the Pre- regions  
Despite of the high complexity of BDNF gene (see Paragraph 1.5.2.2), analyses of 
the predicted translation products of the transcripts revealed they can generate 
three different protein variants which differ only for the signal peptide 
sequence116 (see Figure 1.15). In fact, BDNF as the other neurotrophins, is 
initially produced as pre-neurotrophin and consists of a signal peptide (Pre-
region) following the initiation codon, a Pro-region containing a N-glycosylation 
site and the mature neurotrophin (Mature – region; Figure 1.11). The most 
abundant isoform of BDNF is the PreBDNF1 which is generated by translation of 
almost all BDNF transcripts and has a signal peptide of 19 aminoacids (Figure 
1.12). The transcript containing BDNF exon I  encodes a 50-UTR inframe 
methionine that may serve as an alternative translational initiation site for a 
PreBDNF2 that would contain eight additional N-terminal aminoacids 
(MFHQVRRV; Figure 1.13). The transcript called BDNF VIIb would be capable to 
produce PreBDNF3 which is characterized by additional seven aminoacids to the 
N-terminus of PreBDNF2 (Figure 1.14). 
To reach the Mature form (Mature - M.W. ≈ 14kDa)122 of about 14 kDa, Pre-Pro-
BDNF isoforms (Pre-Pro-BDNF - M.W. ≈ 32kDa) need to be cleaved. Pre-Pro-
BDNF is also able to generate a truncated form of about 28 kDa that arises by a 
different processing mechanism than Mature. Proteolytic cleavage can occur 
either intracellularly or extracellularly. Intracellular cleavage is primarily leaded 
by Furin, a protease owning to the family of convertases and it can take place 
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within the trans-Golgi network and/or immature secretory vesicles123. 
Differently, the extracellular processing of ProBDNF124 can be regulated 
selectively by plasmin and matrix metalloproteinases125,126. Wherever it is 
processed, ProBDNF distribution in the brain seems to almost overlap with 
Mature BDNF localisation127. 
 
Figure 1.15: Scheme of the BDNF variants. 
 
ProBDNF is not only a precursor of the mature and active form of BDNF, but it 
also seems to carry out important biological functions. Woo and colleagues103 
demonstrated that ProBDNF is capable of inducing apoptosis in cultured 
sympathetic neurons through the activation of a complex formed by p75NTR and 
sortilin. Both the receptors were found to be necessary for the induction of cell 
death. These findings reveal a previously unknown functional role of PreBDNF 
opposite to the role played by Mature BDNF. Therefore, cell survival and 
synaptic plasticity seems to depend on the correct balance of these two forms.  
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1.5.2.4 BDNF mRNA trafficking in dendrites  
In recent years, several studies have revealed that neuronal protein expression is 
carried out by a distributed network of translational machinery even at 
extrasomatic locations, allowing selective protein synthesis within constrained 
subcellular domains128,129. Moreover, it is well established that synaptic efficacy 
in a long-term memory process depends on the accurate delivery of newly 
synthesised proteins to the postsynaptic area130,131. Defection in dendritic 
transport and/or translation are closely related to cognitive impairment and it 
highlights the central role of dendritically localised mRNA in learning and 
memory mechanisms132. In literature, many experimental arguments that 
support the existence of a somatic-independent translation mechanism are 
described. First, Bodian133 observed the existence of ribosomes in dendrites. 
Then, Steward & Levy134 supplied increasing experimental evidences for the 
presence of protein synthesis essential machinery both in dendrites and sub-
synaptic compartments. Subsequent studies showed the specific localization of 
polyribosomes beneath synaptic connections, suggesting that protein synthesis 
could be regulated locally135,136,137. With the scientific improvement of certain 
techniques, such as immunohistochemistry and electron microscopy, it was 
possible to provide a more accurate localisation of ribosomes, along with other 
translational elements such as rRNAs, tRNAs, translation factors, endoplasmic 
reticulum (ER), and Golgi apparatus (GA)138,139,140,141,142,143. Meanwhile, major 
                                                          
128
 Steward, Wallace, Lyford, Worley; Neuron, 1998, 21: 741 
129
 Sutton, Schuman; J. Neurobiol., 2005, 64: 116 
130
 Nguyen, Abel, Kandel; Science, 1994, 265: 1104 
131
 Reymann, Frey; Neuropharmacology, 2007, 52, 1: 24 
132
 Cohen-Cory, Kidane, Shirkey, Marshak; Dev. Neurobiol., 2010, 70, 5: 271 
133
 Bodian; Proc. Natl. Acad. Sci. U S A, 1965, 53: 418 
134
 Steward, Levy; J. Neurosci., 1982, 2: 284 
135
 Steward, Fass; Prog. Brain Res., 1983, 58: 131 
136
 Steward; J. Neurosci., 1983, 3: 177 
137
 Ostroff, Fiala, Allwardt, Harris; Neuron, 2002, 35: 535 
138
 Steward, Falk; J. Neurosci. Res., 1985, 13: 75 
139
 Steward, Reeves; J. Neurosci., 1988, 8: 176 
Introduction 
30 
breakthroughs occurred in the basic field of cellular biology concerning the 
neuronal secretory pathway, and particularly its primary organelles – ER and 
GA144. Neuronal ER was identified as a mesh-like endomembrane that extends 
from the nuclear envelope to the cell periphery145, subdividing then into ER exit 
sites and specialised ribosome-free sub-domains which are distributed 
throughout dendrites146,147. After exiting from ER, cargos are directed to GA 
which presents both somatic and dendritic distribution in neurons148,149. Such 
discoveries helped to understand what role the secretory pathway plays in 
complex neuronal processes, represented in Figure 1.16. Experiments in isolated 
synaptic membrane fractions150,151,152,153 and hippocampal slices154 confirmed 
that protein synthesis can in fact occur outside the cell body. Then, Eberwine 
and colleagues155,156 proved that dendrites have the ability to translate 
exogenous RNA, which later suggested the existence of translation hotspots in 
dendrites157,158 that generates the proteins necessary for dendritic function159. 
Likewise, it was demonstrated that both cytoplasmatic and membrane proteins 
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can be effectively synthesised in dendrites, and particularly newly synthesised 
receptors can be immediately inserted into dendritic membranes160. The 
concluding evidence of a role of dendritic mRNAs in long-term plasticity came 
from Kang & Schuman161. They revealed that neurotrophin-induced plasticity in 
rodent hippocampus required local protein synthesis, and most significantly, 
potentiation endured even after cell bodies of pre- and postsynaptic neurons 
were detached from their dendrites. Studies from isolated hippocampal 
dendritic fields also support the previous results162,163. In addition, a recent study 
demonstrated that synaptic activity controls the dendritic spine morphology by 
modulating sEF2-Dependent BDNF synthesis. In fact the protein synthesis in 
dendritic spines might be regulated during nascent peptide elongation by 
eukaryotic elongation factor 2 (eEF2), which controls the transit of mRNA 
through the ribosome. eEF2 phosphorylation by eEF2 kinase (eEF2K) usually 
slows protein translation and elongation164,165 but increases the translation of 
some mRNA localised in dendrites166,167,168,169,170. Dendritic synthesis of BDNF 
protein is dependent on eEF2 phosphorylation in dendrites: specifically BDNF 
synthesis is reduced in the absence of eEF2K and increased in neurons 
overexpressing constitutively active eEF2K. This indicates that spine plasticity 
and structure are finely tuned by eEF2K-eEF2 pathway via the regulation 
dendritic BDNF expression. Alterations in this pathway can compromise long-
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lasting spine plasticity and lead to cognitive dysfunction171. Though the biological 
significance of local protein synthesis in neuronal function is still controversial, 
all the evidence strongly argues that local mRNA translation in dendrites is 
essential to synaptic plasticity maintenance172. 
 
Figure 1.16: Current model of distribution of protein biosynthetic compartments in 
dendrites and spines, as described by Tongiorgi
173
. 
 
1.5.2.5 Mechanisms of BDNF mRNA trafficking to dendrites  
Although it is well-established that BDNF is stored in both axonal and dendritic 
compartment174,175,176,177 the mechanism of their targeting to axons or dendrites 
is still not entirely clear. Both mRNAs have been identified and amplified from 
                                                          
171
 Verpelli, Piccoli, Zibetti, Zanchi, Gardoni, Huang, Brambilla, Di Luca, Battaglioli, Sala; J. 
Neurosci., 2010, 30, 17: 5830 
172
 Tyler, Alonso, Bramhan, Pozzo-Miller; Learn. Memory, 2001, 9: 224 
173
 Tongiorgi; Neurosci. Res., 2008, 61: 335 
174
 Wetmore, Olson, Bean; J. Neurosci., 1994, 14: 1688 
175
 Cabelli, Allendoerfer, Radeke, Welcher, Feinstein, Shatz; J. Neurosci., 1996, 16: 7965 
176
 Conner, Lauterborn, Yan, Gall, Varon; J. Neurosci., 1997, 17: 2295 
177
 Fawcett, Aloyz, McLean, Pareek, Miller, McPherson, Murphy; J. Biol. Chem., 1997, 
272: 8837 
Introduction 
33 
dendritic growth cones155; however, the location of these two mRNAs in mature 
neurons was initially contentious176,178,179,180. 
Tongiorgi and colleagues117 were the first to provide  clear evidence of the BDNF 
mRNAs localisation in the dendrites of cultured hippocampal neurons. Under 
basal conditions both mRNAs had somato-dendritic localisation, whereas in 
response to a tetanic electrical stimulation they were mainly located at the distal 
portion of dendrites. The electrical activity-dependent dendritic targeting of 
BDNF mRNAs appears to be mediated by the activation of NMDA receptors, as 
seen by in vivo and in vitro studies117,119. The accumulation of both mRNAs in 
distal dendrites requires the influx of Ca2+ through glutamate receptors, as well 
as through voltage-gated L-type Ca2+ channels118. Endogenous BDNF, when 
released from depolarised neurons, acts by binding to its receptor, inducing the 
dendritic targeting of both mRNAs through an autocrine loop. This process 
appears to be dependent on the activation of TrkB-mediated PI-3K intracellular 
signalling pathway118, whose known downstream effectors are also involved in 
the regulation of mRNA translation181. It is becoming increasingly clear that 
mRNA transport in glial and neuronal processes depends upon multiple dendritic 
targeting elements182,183. These targeting elements were mainly found in the 
3’UTR of the transported mRNAs but are also present in the coding region of 
some dendritic mRNAs184,185,186. 
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In the case of BDNF mRNA, An and colleagues demonstrated that under basal 
conditions, BDNF short 3’UTR mRNAs have somatic localisation, whereas long 
3’UTR mRNAs are also present in dendrites. Mutant mice with a deletion of long 
3’UTR have a deficient targeting of BDNF mRNAs, and consequently an impaired 
LTP187. However, this simple mechanism has been recently challenged by the 
recent discovery that BDNF mRNAs with short 3’UTR can be efficiently 
transported in dendrite of neurons stimulated by KCl depolarisation188.  
1.5.2.6 BDNF and neuropsychiatric disorders 
BDNF was firstly identified within the human serum in 1995 by Rosenfeld98. 
Moreover, it was reported that BDNF could cross the blood brain barrier189 and 
that BDNF levels in brain and serum underwent similar changes during 
maturation and aging processes in rats190, suggesting that serum BDNF levels 
may reflect the BDNF levels in the brain.  
Alterations in BDNF expression contribute not only to epilepsy, Alzheimer’s, 
Huntington’s and Parkinson’s disease 74,75,191,192,193 but also to various 
neuropsychiatric pathologies. 
Psychotic conditions: numerous experimental evidences indicate that an 
alteration in BDNF mRNA and protein levels could lead to these conditions and 
BDNF was also found to be linked with cognitive impairment typical of many 
schizophrenic patients194. It is possible to find a significant role of this 
neurotrophin also in bipolar disorders and ADHD. A number of studies have 
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reported altered levels of this neurotrophin in serum in different psychotic 
subjects but, regarding schizophrenia, there are controversial data (no variation 
of BDNF in serum see ref.202,203,195- significative decrease see ref.196,197,198,199). 
Depression: evidences suggesting that BDFN is involved in the pathophysiology 
of depression derives from the observation of the effects of antidepressant 
drugs. It has been extensively demonstrated that different classes of 
antidepressants significantly increased the expression of BDNF200,201.  
It has been proposed that the correct modulation of the ratio between Mature 
BDNF and its precursor may play an important part in the pathogenesis of 
depression202. This consideration has been proved to be true in Alzheimer’s 
disease, a pathology that shares many common aspects with neuropsychiatric 
disorders203,204. 
Reviewing data about BDNF biology and its relationship with neuropsychiatric 
disorders emphasise how little is still known. Anyway, it is evident that this 
molecule plays a fundamental role in brain health and in cognitive processes and 
it seems reasonable that even a single alteration of its highly complex regulation 
may lead to a pathological condition. New scientific findings have shifted the 
attention towards the importance of ProBDNF biological functions in these 
disorders. It appears clear that having pure antibodies directed towards Pre- 
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regions of BDNF may be associated with the already existing anti-Mature BDNF 
antibodies to better understand how it is expressed in neurons and also to set 
ELISAs assay for the evaluation of the ProBDNF levels in blood.  
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2. Aim of the study 
This project is part of cooperation between two research groups of the 
University of Trieste (Applied and Computational Biocatalysis Group of the 
Department of Chemical and Pharmaceutical Sciences and the Laboratory of 
Molecular and Cellular Neuro-anatomy of the Department of Life Science) and 
the company SPRIN S.p.A. 
Despite the numerous data regarding the role of BDNF, of its isoforms and 
precursor, described in the previous section, the trafficking of BDNF in neurons 
in not well understood. In fact BDNF is a secretory protein and these classes of 
molecules are usually processed in the rough endoplasmic reticulum and the 
Golgi apparatus which are very sparse and dynamic in the dendritic and axonal 
processes of neurons.  
Nowadays the only commercial antibodies available on the market are directed 
towards Pro- and Mature region but not towards the different signal peptides. 
Since quantification of ProBDNF and Mature BDNF in human serum is considered 
a promising biomarker of neuropsychiatric diseases, the possibility to further 
differentiate between BDNF isoforms appears particularly attractive in order to 
develop novel and more accurate tools for compound screening, as well as for 
the diagnosis and the follow-up of medical treatments of these disorders. 
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This Ph.D. project can be divided in two principal fields: 
1. Technological: development of a method for the purification of 
antibodies directed towards BDNF isoform precursors and Mature form. 
2. Biological: application of purified antibodies for immunochemical assays 
in order to study the trafficking of BDNF in neuronal cells. This is a 
general biological question related to all secretory proteins produced in 
neuronal dendrites and axons. 
 
Moreover, due to the applicability of the affinity chromatography principles to a 
wide range of different molecules, the future possibility of scaling-up this 
procedure has been investigated thanks to a project focused on the affinity 
purification of recombinant human albumin during an Erasmus period at 
Novozymes Biopharma UK Ltd. 
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3. Results and Discussion 
About 30% of the proteome of an organism is made up of secreted proteins 
including different classes of molecules such as cytokines, chemokines, 
hormones, digestive enzymes, antibodies, toxins, extracellular proteins. For this 
reason, the regulation of the secretory pathway of proteins is an extremely 
complex and fascinating problem. 
A fundamental role is played by short peptidic sequences, defined signal peptide 
that, as reported in the literature, control most of the steps of the secretory 
pathway205,206. 
 
Figure 3.1: Structure of a signal sequence with the characteristic hydrophobic region (in 
black)
207
. 
To understand the importance of these sequences it may be useful to analyse a 
well-known specific case in molecular biology: the targeting to the rough 
endoplasmic reticulum. 
The rough endoplasmic reticulum (RER) is an organelle of vegetal and animal 
eukaryotic cells and it consists of series of folded membranes forming cavities. 
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The term “rough” refers to the fact that the cytoplasmic side of its membranes 
has many ribosomes whose function is to synthesise proteins. Once the protein 
has been successfully synthesised and folded, it is incorporated into a vesicle to 
follow its specific secretory pathway: 
 Secretion outside the cell 
 Release into the cytoplasm 
 Transport into the Golgi apparatus for post-translational modifications 
 
To start this process at the end of the proteic synthesis at ribosomal level, a 
hydrophobic N-terminus sequence of about 5-20 aminoacids, called signal 
peptide, is required. This sequence is recognised by a specific complex of 
approximately 300bp RNA and six different proteins named signal recognition 
particle (SRP)208. 
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Figure 3.2: Scheme of the interaction among Signal peptide-SRP-Traslocon. The figure 
shows the role of the signal recognition particle (SRP) in binding to the nascent, N-
terminal signal sequence of a protein destined for insertion into the plasma membrane or 
for secretion in a eukaryotic cell. After binding the signal sequence, the SRP docks the 
actively synthesising ribosome on the Translocon by first binding to a nearby SRP receptor 
embedded in the endoplasmic reticular membrane. In the course of targeting the 
ribosome to the Translocon, the SRP and the SRP receptor both hydrolyze bound GTP to 
GDP. The SRP exchanges GDP for GTP when it engages a new signal peptide. 
 
The interaction between the two molecules gives as a result, a temporary stop of 
the protein translation and the following interaction of the complex Ribosome-
protein-SRP with its receptor (SRP receptor) placed on the surface of the 
endoplasmic reticulum. At this stage the interaction between the rising protein 
and the Sec61206, a channel also defined Traslocon occurs. 
Due to this interaction, the insertion of the protein into the lumen of the 
reticulum, the cleavage of the signal peptide, the resume of transduction and the 
folding of the protein by specific molecular chaperon starts209. 
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Figure 3.3: Cleavage of the signal peptide operated by a peptidase
207
.  
In addition to this process, there are many observations reported in the 
literature concerning the role of the signal peptide such as modulation of the 
secretion and the efficiency of translocation210, and prevention of the misfolding 
of Pre-proteins211. Alterations in the mechanism of signal peptide are correlated 
with specific diseases such as Zellweger syndrome or Adenoleukodistrophy212. 
These observations confirm the essential role of the signal peptide and how it is 
still not well known. For this reason this Ph.D. study has been focused on the 
investigation of the signal peptides of BDNF. 
As already highlighted in the introduction (section 1.5.2.3) the signal peptides 
determine the Pre- region (see Figure 1.15) and contribute to define three 
                                                          
210
 Bridgham, Carroll, Thornton; Science, 2006, 312: 87 
211
 Collier, Strobel, Bassford; J. Bacteriol., 1990, 172: 6875 
212
 Yik, Steinberg, Moser, Moser, Hacia; Hum. Mutat., 2009, 30: 467 
Results and Discussion 
43 
different isoforms (Pre1, Pre2, Pre3): only the first two isoforms exhibit the 
characteristics of a typical signal sequence while isoform 3 is only a signal anchor 
without a recognition site and does not come into cleavage. 
Another important observation is related to the correlation between Pro-, 
Mature form and neuronal activity. The Mature form is correlated with the long 
term potentiation (LTP) during the high frequency neuronal stimulation while 
the Pro- form is connected to the long term depression (LTD). The concentration 
of Pro- and the Mature form depends on the proteolytic cleavage occurring 
approximately in the middle of the precursor form. It has been demonstrated 
that the proteolytic cut is dependent to the high frequency neuronal activity, 
balancing the amount of the Pro- and Mature form213. 
Moreover, the Pre- regions of BDNF seem to have distinct functions in different 
neuronal populations suggesting that they can enter into specific physiological 
processes214. It has been also suggested that the Pre- proteins are not only 
transient structures between the immature and the Mature form of BDNF but 
play a key-role at post-natal level. In particular, their role was proven in the 
development of axons, in dendritic spine sprouting and in synaptic 
maturation215. 
All these premises justify the particular attractiveness in order to better 
understand the mechanisms that regulate the processing of these signal 
peptides and the consequent interest in the development of an effective 
purification method for PreBDNF antibodies to utilised in immunochemical trials. 
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3.1 BDNF signal peptides as antigens 
The first step for the development of an effective chromatographic resin for the 
purification of specific antibodies was the design of polyclonal antibodies. In 
addition to the antibodies against the BDNF, Pro- and Mature form, already 
present on the market, three antibodies designed to recognise specifically the 
three different PreBDNF protein variants (PreBDNF1, PreBDNF2 and PreBDNF3) 
were produced.  
The identification of BDNF antigenic sites and the production of the polyclonal 
antibodies were already done during the Ph.D. study of Dr. Leone (Figure 3.4). 
For the identification of BDNF antigenic sites parameters such as hydrophobicity 
and antigenicity index using two different appropriate softwares (JaMBW, 
Peptideselect design tool-Invitrogen) were evaluated. Once recognised the most 
promising sites, the effective exposure on the molecule surface through the 
analysis of the three-dimensional crystallographic structure of Mature BDNF was 
performed216,217.  
Each polyclonal antibody was produced in rabbit, starting from the synthesis of a 
peptide (EzBiolab, USA) corresponding to the antigenic sequence identified as 
described in the previous paragraph. To maximise the rate of success, a double-
chance strategy for the production of the antibodies based either on the home-
made production (by the Animal facility at the University of Trieste) or on the 
externalisation of the process (by Pacific Immunology) was followed. With the 
final sacrifice, 50ml of each serum was obtained. Combination of these two 
strategies allowed us to choose the best antiserum for each of the antibodies 
planned (section 3.2). 
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Figure 3.4: Schematic representation of the plan for the production of the antiBDNF 
antibodies. 
Since the specific antibodies were directed against the different PreBDNF 
isoforms, rabbits were immunised with peptides corresponding to these specific 
sequences: therefore it was important to check if the folding of the Pre- peptides 
(immuno peptide) used for the immunisation corresponded to the folding of the 
respective real Pre- sequence. The capability of specific IgGs to recognise the 
BDNF signal peptide was assayed by experimental validation and also by the 
comparison of the folding of the peptide used for the immunisation with the 
folding of the corresponding complete sequence.  
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3.1.1 Folding of the peptide sequences 
The peptides used for the rabbit immunisations derived directly from the BDNF 
signal peptide; more specifically, the immunisation peptides are part of each 
BDNF signal peptide. (Table 3.1) 
Table 3.1: Sequences corresponding to the different Pre- peptides. 
Signal Peptide Sequence 
PreBDNF1 signal mtilfltmvisyfgcmka 
PreBDNF2 signal mfhqvrrvmtilfltmvisyfgcmka 
PreBDNF3 signal mqsreeewmfhqvrrvmtilfltmvisyfgcmka 
  
Immuno peptides Sequence 
PreBDNF1 tmvisyfgmka 
PreBDNF2  fhqvrrv 
PreBDNF3 mqsreeew 
 
In order to verify that each immunisation peptide assumed a shape very closed 
to the corresponding signal peptide, a computational strategy was developed. 
The idea is based on the comparison of the folding of the BDNF signal peptide 
with the folding of the correspondence immunisation peptide. 
Each of these sequences was firstly generated as a linear structure with the 
software PyMOL218 so that the structures were defined into the OPLS-AA force 
field219 and then minimised using the software GROMACS220. After the first 
minimisation step, each peptide was subjected to a first 10ns molecular dynamic 
(MD) simulation in order to equilibrate the system (Paragraph 5.4.2).  
Therefore, after a second minimisation step, each structure was submitted to 
the productive operation: a series of 200ns MD simulation was performed, after 
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each MD simulation a structure clustering calculated on the Cα of the peptide 
was performed, the average structure of the most populated cluster was 
minimised and dinamised again for another 200ns. These operations were 
repeated until each sequence was dinamised for a total time of 1μs. The average 
structure of the most populated cluster of the last MD simulation was 
considered as the folded structure of each sequence. 
3.1.2 Folding comparison 
Once the foldings were calculated, the structures were compared in order to 
verify the similarities between the Pre- immuno sequence and the corresponding 
Pre- signal sequence. The sequences were compared by performing the 
superimposition between the related structures (i.e. Pre1 immuno superposed 
to Pre1signal); the structures were superposed with the align tool of the 
software PyMOL by aligning the Cα of the structures, similarities have been 
evaluated by visual inspection and by computing the RMSD for each 
superimposition. 
The results of these superimpositions are represented in Figure 3.5. 
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Figure 3.5: Superimposition of the Pre- immuno sequences in green with the relative Pre -
signal sequences in cyan. 
 
These superimpositions show RMSD values of 1.54 Å, 2.12 Å and 3.39 Å for the 
Pre1, Pre2 and Pre3 sequences respectively.  
Concerning the similarities of the conformation of the immune sequences with 
their relative signal sequences, the RMSD value increases from Pre1 to Pre3; this 
fact is understandable considering the length of the signal sequence, more 
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specifically the Pre1 signal sequence has 16 aminoacids less than the Pre3 signal 
sequence. Since the calculation of the most probable conformation with MD 
simulation require an appropriate simulation time and this depends on the 
number of atoms simulated (the high in the number of the simulated atoms, the 
high is the number of the possible conformation that a given molecule can 
assume); it is clear that the immune sequences require a short simulation time 
and 1μs is appropriate. The same 1μs is appropriate also for the Pre1 signal and 
Pre2 signal sequences since also the secondary structure is correctly computed. 
The Pre3 signal sequence requires a simulation time longer than 1μs to be 
correctly calculated and this low accuracy is the reason for the higher RMSD 
value if compared with the superimposition of the other related sequences. 
Nevertheless, even 3.39 Å is not a high value for this kind of calculation and 
superimposition, but this value represents a satisfactory level of 
superimposition. 
By looking at this data it is possible to conclude that the immune- and their 
relative signal peptides have a very similar folding, so that, the antibodies 
produced by the rabbits can be considered towards the correct epitopes. 
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3.2 Choice of the serum 
For this research rabbit sera immunised towards the signal peptides PreBDNF1, 
PreBDNF2 and PreBDNF3, the first portion and the central part of the Mature 
protein (respectively Mature1-12 and Mature91-102) were available. Three sera 
for each antigen were made by the standard protocol immunisation of rabbits. 
Two of these were produced by an external laboratory (Pacific Immunology), one 
by the Animal facility of the University of Trieste. 50ml of each serum were 
obtained, and the highest antibody titre into the serum was chosen from this 
pool by using a Dot Blot assay. For the choice of the serum its antigens at various 
concentrations were immobilised on a nitrocellulose membrane (as described in 
section 5.4.3.1) and the efficiency of the antibodies was measured in terms of 
the positive response for the antigen.  
In Figure 3.6 it is possible to observe that all the sera towards PreBDFN1 
recognise their immobilised antigen. The Pacific Immunology serum 1348 shows 
a slight decrease of the antibodies concentration compared to 1347. The serum 
produced by the University of Trieste has good capability in antigen recognition, 
however this response could be due to non-specific interactions of the 
antibodies with the target molecule. In light of this, the Pacific Immunology 
serum 1347 was chosen for further experiments. All the sera were assayed with 
the same method. Listed in Table 3.2 are the sera with the highest antibody 
concentration chosen for this study. 
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Figure 3.6: Dot Blot of rabbit serum immunised towards PreDBNF1 for the determination 
of the antibodies concentration. The antigen immobilised on the nitrocellulose membrane 
with the related concentrations are indicated by the arrows. BDNF (rabbit BDNF - 
Promega) and hBDNF (Human isoform of BDNF - Alomone) represent the whole BDNF 
molecule (Pre+Pro+Mature). The results show the capability of the antibodies of the 
serum to recognise the Pre- portion (both when only PBS or PBS+BSA buffer are utilised 
during the immobilisation) and also the Pre- fraction in the whole BDNF molecule. 
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Table 3.2: Immunised rabbit sera available. Sera with the highest antibody concentration 
are highlighted in cyan. 
Epitope Serum 
PreBDNF1 
Pacific Immunology 1347 
Pacific Immunology 1348 
Stabularium Units “Piero” 
PreBDNF2 
Pacific Immunology 1349 
Pacific Immunology 1350 
Stabularium Units “Deutero” 
PreBDNF3 
Pacific Immunology 1351 
Pacific Immunology 1352 
Stabularium Units “Poss” 
Mature1-12 
Pacific Immunology 1353 
Pacific Immunology 1354 
Mature91-102 
Pacific Immunology 1341 
Pacific Immunology 1342 
Stabularium Units “Quarto” 
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3.3 Purification of anti-BDNF antibodies 
After the individuation of the highest antibody concentration sera, the study was 
focused on the purification of the anti-BDNF antibodies. In order to enhance the 
purity of the final product, the first step in the purification process was the 
separation of  IgG class antibodies. In fact the anti-BDNF antibodies produced 
were part of immunoglobulins class G. 
For the purification of this class of molecules, Protein-A chromatography is 
extensively used (see 1.4.1). On the market there are numerous Protein-A (both 
wild type and recombinant) products for this purpose. However, in order to 
monitor every single chromatographic step of the chain, only “homemade” 
resins, developed and produced within this Ph. D. project, were used. With this 
purpose, an immobilised nProtein-A support was prepared. 
 
3.3.1 Preparation of nProtein-A based matrix 
3.3.1.1 Reproducibility of DBC 
In order to develop the new nProtein-A based support, preliminary DBC tests 
were necessary. Dynamic Binding Capacity (DBC) is the amount of purified target 
protein per ml of matrix that will be recovered under standard operational 
conditions (at certain flow rate, loading condition etc.) 221,222. Tests with nProtein-
A Sepharose® 4 Fast Flow using the protein purification system ÄKTA-Prime® (GE 
Healthcare) were performed to ensure both the reproducibility of the DBC value 
stated by the producer (GE Healthcare) and to validate the DBC protocol for the 
quantitative tests on immobilised samples.  
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Figure 3.7: AKTA prime purification system. 
 
nProtein-A Sepharose® 4 Fast Flow is an affinity medium designed for the 
purification of monoclonal and polyclonal antibodies. The DBC value declared 
from the producer is 30 - 35mg of human IgG/ml of drained medium. For the 
measurement of DBC, nProtein-A Sepharose® 4 Fast Flow and human IgGs 
lyophilized (Cell Sciences) were used. Human IgGs instead of rabbit IgGs were 
selected for these preliminary tests because they are more abundant and exhibit 
the same binding strength to nProtein-A of rabbit IgGs. Moreover, polyclonal 
IgGs were chosen in order to reproduce the same variability of recognition and 
antigen binding capability normally detected within a polyclonal population of 
antibodies23,66,223. 
The determination method for DBC showed good reproducibility and an average 
value of 32.68mg of IgGs per ml of nProtein-A Sepharose® 4 Fast Flow was 
obtained, value that is in line with that declared by the producer (35mg of 
IgG/ml of support) (see Table 3.3). 
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Table 3.3. Results of the test for the reproducibility of the DBC value. 
Experiments  Recovered IgG (mg/ml) Volume of elution (ml) 
Trial 1 31.95 5.50 
Trial 2 32.66 5.50 
Trial 3 33.44 5.60 
Average 32.68  
Declared value by GE 35 mg IgG/ml  
 
3.3.1.2 Immobilisation of nProtein-A on a new agarose based support 
The first step for the development of the nProtein-A resin was the choice of the 
most appropriate polymeric matrix. For this purpose characteristics like resin 
porosity, particle size and a functionalization chemistry suitable for the covalent 
immobilisation were considered. In order to have the possibility to compare the 
obtained results, an agarose based support was chosen.  
The immobilisation protocol was developed by Design of Experiment approach. 
This methodology enables both a rational collection of data and a statistical 
analysis for the identification of the significant experimental variables and to 
maximise the extraction of information.  
A full experimental design was used with four different variables. The variables 
were selected among those which significantly affect the immobilisation process 
of enzymes and proteins. For each variable, 2 different levels (- and +) were 
chosen, corresponding to the “low” (-) setting and “high” (+) setting.  
Using the software MODDE 8, a pool of 16 different experiments and 3 centres 
were set224. 
At the end of the immobilisation all preparations were characterised in terms of 
water retention and amount (%) of bound nProtein-A. (See Table 3.4). 
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Table 3.4. Experimental design for nProtein-A immobilised on agarose. Results of water 
retention and % of bound nProtein-A are in the blue columns. The last three results (N17, 
N18, N19) represent the centres.  
Exp. 
Variab. 
1 
Variab. 
2 
Variab. 
3 
Variab. 
4 
Water 
Retentiona 
nProtein-A 
Bounded b 
     
% % 
N1 - - - - 91 62 
N2 + - - - 91 65 
N3 - + - - 90 59 
N4 + + - - 90 62 
N5 - - + - 92 97 
N6 + - + - 91 92 
N7 - + + - 90 99 
N8 + + + - 90 96 
N9 - - - + 90 60 
N10 + - - + 91 68 
N11 - + - + 91 67 
N12 + + - + 90 59 
N13 - - + + 90 97 
N14 + - + + 89 96 
N15 - + + + 90 99 
N16 + + + + 90 98 
N17 0 0 0 0 90 80 
N18 0 0 0 0 90 76 
N19 0 0 0 0 90 76 
a 
Water retention was quantified on the basis of the weight difference 
between wet and dry resins (dried for 6 hours at 110°C). 
b  
nProtein-A content was determined by Pierce assay. 
 
3.3.1.3 Evaluation of DBC and analysis of the variables   
To define the efficiency of the immobilised nProtein-A on a new agarose based 
support, the DBC value of each one was measured. This value was also useful to 
analyse how the variables of immobilisation affect it. 
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The evaluation of the effect of the variables based on the DBC values in a large 
experimental area requires a high number of experiments whereas a rational 
experimental design for the determination of DBC allows to study a wide 
experimental area with a limited number of experiments. A second experimental 
design, based on samples prepared according to the first experimental design 
was planned for the determination of purification capacity of the samples. 
Two different flow rates were selected (0.5ml/min and 1.7ml/min) and each 
preparation was assayed as described in paragraph 5.4.5.3. In this way it was 
possible to measure the DBC both for high and low flow within the 
recommended range for nProtein-A Sepharose® 4 Fast Flow (included between 
0.17ml/min and 1.7ml/min)60. 
For DBC determination of human IgGs of two different batches (B1 and B2) were 
used, in order to have comparable data with the determination of DBC with 
nProtein-A Sepharose® 4 Fast Flow reported in Table 3.3. The amount of IgGs 
used to load the column of nProtein-A immobilised on agarose was calculated 
referring to DBC value of 30 - 35mg/ml declared for nProtein-A Sepharose® 4 
Fast Flow; a 2 time excess was used in order to ensure the saturation of all the 
binding sites of the column. 
The DBC was calculated on the basis of the amount of recovered IgGs from the 
elution per ml of resins.  
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Table 3.5. Experimental design for nProtein-A immobilised on agarose. Results of DBC and Volume of elution are in the blue columns. DBC 
values measured with a second batch of IgG (B2) are reported in red, in blue are the values measured with IgG of batch 1 (B1). 
Exp. 
Variab. 
1 
Variab. 
2 
Variab. 
3 
Variab. 
4 
Water 
Retention a 
nProtein-A 
Bounded b 
Flow Rate 
Order of 
run c 
DBC d 
Volume of 
Elution 
     
% % ml/min  mg/ml ml 
N1 - - - - 91 62 0.5 I 0.97 2.00 
N2 + - - - 91 65 1.7 II 2.00 5.00 
N3 - + - - 90 59 1.7 II 1.68 3.00 
N4 + + - - 90 62 0.5 II 4.04 3.50 
N5 - - + - 92 97 1.7 II 9.68 3.75 
N6 + - + - 91 92 0.5 I 19.33 8.00 
N7 - + + - 90 99 0.5 I 6.40 2.75 
N8 + + + - 90 96 1.7 II 9.77 5.25 
N9 - - - + 90 60 0.5 II 2.67 2.50 
N10 + - - + 91 68 1.7 I 5.56 4.75 
N11 - + - + 91 67 1.7 I 2.04 3.00 
N12 + + - + 90 59 0.5 I 11.95 5.00 
N13 - - + + 90 97 1.7 I 5.16 3.50 
N14 + - + + 89 96 0.5 II 17.03 4.00 
N15 - + + + 90 99 0.5 II 4.16 1.80 
N16 + + + + 90 98 1.7 II 13.44 3.75 
a 
Water retention was quantified on the basis of the weight difference between the wet and dry resins (heated for 6h at 
110°C).  
b 
Bounded nProtein-A was determined by Pierce assay. 
C 
The DBC will be evaluated by following the flow rate reported 
in the table. The order column  determines the sequence of the execution of the purification step. 
d 
Amount of eluted IgGs was 
determined by UV280nm . Column bed height 6cm, inner diameter 0.66cm 
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 From a first analysis of the collected results, as reported in Table 3.5, the best 
preparation, in terms of DBC and volume of elution, was the experiment N14 
that gives a DBC of 17.03mg IgG per ml of support with an elution volume of 
4.00ml. Experiments N16 and N12 gave respectively a DBC of 13.44 and 11.95mg 
IgG per ml of support and an elution volume of 3.75 and 5.00ml. Experiment N6 
has a high DBC value (19.33mg IgG) but a very large volume of elution (8.00ml). 
It has to be underlined that a desirable chromatographic purification step should 
have a high DBC with a small volume of elution (as a comparison see Table 3.3: 
typical elution volume of nProtein-A Sepharose® 4 Fast Flow is 5.5ml).225 
Experiments N5 and N8 have a comparable value of DBC (9.68 – 9.77mg IgG/ml 
support) and volume of elution (3.75 – 5.25ml). Experiment N7 has an 
intermediate value of DBC and volume of elution (6.40mg IgG/ml support – 
2.75ml). Experiment N10 has DBC similar to N7 (5.56 – 6.40mg IgG/ml support) 
but a double volume of elution (4.75 – 2.75ml). Experiments N1, N2, N3, N9, N11 
are similar with low values of DBC, in the range of 0.97 – 2.67mg IgG/ml support, 
and volumes of elution included between 2.00 and 5.00ml.  
Overall experiments N5, N7, N15, N12, N14 and N16 have high values of DBC and 
small volumes of elution in comparison to the other trials. 
For this experimental designs 4 variables were considered. By analysing each one 
it has been possible to identify that variables 1 (V1) and variables 2 (V2), the 
interaction between them and the used IgG batch significantly affect the 
performance of the chromatographic support.(Figure 3.8) 
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Figure 3.8: Plot of the analysis of the effects of the variables. Label: 1. Batch of IgG; 2. 
Variable 2; 3. Variable 1; 4. Interaction between V1 and V2; 5. Interaction between V2 
and V3; 6. Interaction between V3 and V4; 7. Order of the run; 8. Interaction between V1 
and V3; 9. Interaction between V1 and V4; 10. Interaction between V1 and flow rate; 11. 
Variable 4; 12. Interaction between V1 and order of the run; 13. Variable 3; 14. Flow rate. 
 
3.3.1.4 Replicated experiments 
Initially, experiments N4, N12, N13 and N14 were carried out with batch#2. In 
order to verify why 2 out of 4 values were higher than the average values for the 
other preparation assayed with batch#1, some experiments (Reported in Table 
3.6) were performed by means batch #2. The DBC values of repeated 
experiments measured with batch#2 of IgG were higher than the values 
achieved with batch#1. A possible reason for these different values is the 
different binding capacity to nProtein-A of polyclonal population of antibodies of 
different batches66. Another reason could be the storage condition. In fact the 
first batch of IgG was stored at -18°C, the second batch at +4°C. Repeated thaws 
can affect the tertiary structure of the protein with a change of the conformation 
and a consequent variation in recognition and binding to nProtein-A. 
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Table 3.6. Matching between first and replicated experiments (in bold) of the design for nProtein-A immobilised on agarose. Results of DBC and 
Volume of elution of the firs and the replicated experiments were reported in the blue columns. 
Exp. 
Variab. 
1 
Variab. 
2 
Variab. 
3 
Variab. 
4 
Water 
Retention a 
nProtein-A 
Bounded b 
Flow Rate 
Order of 
run c 
DBC d 
Volume of 
Elution 
 
    % % ml/min  mg/ml ml 
N5-I - - + - 92 97 1.7 II 9.68 3.75 
N5-II - - + - 90 94 1.7 II 14.05 4.00 
N6-I + - + - 91 92 0.5 I 19.33 8.00 
N6-II + - + - 89 91 0.5 I 25.14 4.50 
N16-I + + + + 90 98 1.7 II 13.44 3.75 
N16-II + + + + 89 97 1.7 II 25.62 5.00 
a 
Water retention was quantified on the basis of the weight difference between wet and dry resins (heated for 6 
hours at 110°C). 
b 
Bounded nProtein-A was determined by Pierce assay. 
C 
The DBC will be evaluated following the flow rate reported in the table. The order column determines the 
sequence of the execution of the purification step. 
d 
DBC was estimated on the mg of recovered IgG for ml of resins. The amount of eluted IgGs was determined by 
measurement of the UV280nm. Column bed height 6cm, inner diameter 0.66cm. 
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3.3.1.5 Exploration of the conditions of immobilisation out of the experimental 
area 
To verify the different response of the immobilised preparation by the changing 
of the immobilisation conditions, it was chosen to explore the conditions of 
immobilisation out of the experimental area.  
By using MOODE 8 it was created a prediction table of DBC (Table 3.7 and Figure 
3.9) with conditions of immobilisation out of the experimental area based on the 
results obtained from the analysis of the experimental design (Figure 3.8).  
Figure 3.9: Contour Plot of predicted DBC (shown within the boxes). Two variables of the 
conditions of immobilisation (V1 and V2) were changed out of the experimental area. 
 
The obtained results show that the predicted values of DBC do not fit with the 
measured values (See Table 3.7), but it is necessary to underline that not all the 
variables of the experiment are located in the explored region (-1; +1). 
Consequently, the optimal operative conditions are located in the previously 
settled range of the variables, and the best sample in terms of DBC and volume 
of elution, the preparation N6, was used for further experiments. 
DBC 
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Table 3.7. Matching between predicted and measured DBC of the optimised experiments 
out of the experimental area. 
Exp. Var.1 Var.2 Var.3 Var.4 
Predicted 
DBC a 
Measured 
DBC a 
Volume of 
Elution 
     mg/ml mg/ml ml 
R1 +1 +1.7 -1 -1 30.00 26.04 5.00 
R2 -1.4 +2.8 -1 -1 29.00 16.95 4.00 
R3 +1.3 +2.1 -1 -1 43.00 30.45 5.00 
R4 +1.7 +2.8 -1 -1 60.00 31.14 5.00 
 
a 
DBC was estimated on the mg of recovered IgG for ml of resins. The 
amount of eluted IgGs was determined by the measurement of the 
UV280 nm 
 
3.3.1.6 Determination of the leaching of nProtein-A from the matrix 
One of the drawbacks of Protein-A chromatography is that the Protein-A ligand 
often co-elutes with the antibody. In the eluted fractions it could be possible to 
find fragments as well as intact Protein-A. It happens often when the purification 
run is performed with a harvested cell culture fluid. The range in molecular 
weight of leached Protein-A fragments vary from 6 to 40 kDa and arise through 
proteolytic cleavage of the interdomain sequences by proteases present in the 
cell culture226. Not only do proteases come from a supernatant cell culture, but 
also buffers, in particular those used for the elution step, can damage the 
Protein-A ligand with a consequent loss of activity and decrease of DBC, and/or 
leaching of fragments which compromise the purity of the final product.  
To evaluate if the buffers used in the purification step can cause leaching of 
Protein-A from the matrix, a protocol to test the column under condition of 
extreme purification conditions was set (Run for 120’ with Binding buffer, 60’ 
with Elution buffer, 30’ with Binding buffer) and a purification, described in 
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5.4.5.3, without apply any antibodies, was carried out. During a chromatographic 
run the elution time of the antibody of interest lasts for an average of 5 - 10 
minutes at most. With the extended exposure of the column to the harsh 
condition of the Elution buffer, it is possible that both intact or fragmented 
Protein-A are leached from the matrix. The UV280 nm of the flow-through was 
monitored along the entire run (Figure 3.10). During the elution step the 
maximum absorbance measured was 0.003 AU when the instrument detected 
some small peaks. Other fluctuations were observed in both the moment of the 
changing of the buffer, probably due to the buffer valve rotation. 
Figure 3.10. Chromatogram of the test for the leaching of nProtein-A. In blue: UV curve; 
Green curve shows the change of buffer during the elution step; Red curve: conductivity. 
 
Moreover, to verify the presence of intact or fragmented nProtein-A, the 
fractions of the chromatographic run were assayed by western blot technique as 
described in 5.4.3.3 by means of goat anti-Protein-A IgG (Genetex) and a 
secondary HRP conjugated, rabbit anti-goat IgG (KPL 14-13-06) both diluted 
1:5000. 
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No signals referred to leached nProtein-A (whole molecule or fragments) in the 
eluted samples, flow-through and washings were detected: nProtein-A is 
strongly bound on the agarose beads. 
 
Figure 3.11: Western Blot of samples collected during the elution. No signals referred to 
leached nProtein-A were detected. On the right: positive control of nProtein-A. 
 
Figure 3.12: Western Blot of samples collected during the loading and the post-elution 
phases. No signals referred to leached nProtein-A were detected. On the right: positive 
control of nProtein-A. 
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Figure 3.13: Western Blot of nProtein-A samples assayed as positive control at different 
concentrations: Line 1: 132µg, Line 2: 66µg, Line 3: 33µg, Line 4: 13µg. 
3.3.1.7 DBCs comparison  
At the end of the study the DBCs of the new agarose matrix and the reference 
product were measured and compared as described in 5.4.5.3 in order to have 
an additional comparison. 
Table 3.8. Results of DBC with EXP N6 and nProtein-A Sepharose 4 FF by using GE 
protocol. 
Experiment DBC a 
Volume of 
Elution 
 
mg IgG/ 
ml support 
ml 
EXP N6 – Trial 1 32.10 4.50 
EXP N6 – Trial 2 36.87 4.75 
nProtein-A Sepharose 4 FF – Trial 1 32.68 5.50 
nProtein-A Sepharose 4 FF – Trial 2 34,92 5.25 
a 
DBC was estimated on the basis of mg of recovered IgG for ml of 
resin. The amount of eluted IgGs was determined by measurement of 
the UV280nm. Column characteristics: bed height 6cm, inner diameter 
0.66cm. 
The measured values both for EXP N6 and nProtein-A Sepharose 4 FF are 
comparable and fit with the DBC value declared by GE Healthcare. In light of this, 
it can be assessed that the new matrix gives performances like nProtein-A 
Sepharose 4 FF.  
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3.3.2 Purification of immunoglobulins G fraction from sera 
During the early phase of this study, the sera with the highest anti-BDNF 
antibodies concentrations were chosen and at this stage, by using the nProtein-A 
resin produced in our laboratory, the whole IgG fraction (anti-BDNF IgG and non-
specific IgG) of each serum was purified as described in 5.4.5.1. This first 
purification step is needed in order to isolate the IgG from the other serum 
proteins, in particular albumin, which is the most abundant one.  
In order to verify that the concentration of the purified antibodies was higher 
than the other serum proteins at the end of this step, the eluted fractions and 
the flow-through were analysed by SDS-Page. Results only related to Pacific 
Immunology serum 1347 are shown (Figure 3.14). 
 
Figure 3.14: SDS-Page of nProtein-A purified IgG. On the left: BSA standard calibration 
curve. On the right purified IgG fractions at different concentrations and Flow-through. 
Red rectangles: light and heavy chains of the IgG. Yellow rectangle: albumin. 
Results were similar for each serum. The presence of IgG antibodies is clearly 
present into the elution fractions with a slightly concentration of albumin, 
probably due to its non-specific interaction with the hydrophilic agarose matrix. 
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It is possible to observe also that the higher concentration of albumin is 
concentrated in the flow-through sample. 
3.3.3 Anti-BDNF antibodies specific resin preparation 
For the development of the columns for the purification of the specific anti-
BDNF antibodies, Pre- and Mature region, a pool of different chromatographic 
matrices, synthetic organic polymers or biopolymers was considered.  
A rigid acrylic resin functionalised with epoxy groups was chosen and in order to 
immobilise the antigens PreBDNF1, PreBDNF2, PreBDNF3, Mature1-12, 
Mature91-102, an approach already used in commercial products was used as 
reference. 
The Sulfolink immobilisation kit59 is widely utilised for this purpose. It is a 6% 
cross-linked agarose which allows the conjugation of peptides containing at least 
one cysteine by means of a spacer arm with a iodoacetyl group that forms a 
thioether bond (Figure 3.15) with the thiol group of cysteine.  
 
Figure 3.15: Sulfolink structure and peptide conjugation mechanism. 
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For an epoxy matrix it is possible to obtain a similar reaction between the epoxy 
and a thiol group.  
O
HS PEPTIDE
S
OH
PEPTIDE
+
 
Figure 3.16: Mechanism of conjugation between an epoxy matrix and a molecule 
containing a thiol group. 
 
Preliminary tests on the epoxy support were carried out in order to verify the 
condition of use and pH 6.5 was chosen as optimal value for the immobilisation 
buffer. Moreover, thanks to the higher reactivity of the thiol compared to the 
amino group of a peptide, with this immobilisation method it is possible to 
obtain a selective coupling of a SH- functionalised target molecule. 
 
3.3.3.1 Synthesis of the antigens 
The peculiar characteristic of the epoxy matrix described in the previous 
paragraph, was taken into account for the synthesis of the antigens and it was 
exploited in order to obtain an oriented immobilisation of the molecules. In fact 
the three antigens directed towards Pre- fraction (PreBDNF1, PreBDNF2, 
PreBDNF3) exhibited different peptidic sequences but all displayed a C-terminal 
cysteine, as reported in Table 3.9. 
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Table 3.9: PreBDNF isoforms peptide sequences (in bold), rabbit  immunisation sequences 
(in black). 
PEPTIDE SEQUENCE 
Pre-1  ThrMetValIleSerTyrPheGlyCys 
Pre-1 
signal 
MetThrIleLeuPheLeuThrMetValIleSerTyrPheGlyCysMetLysAla 
Pre-2 CysPheHisGlnValArgArgVal 
Pre-2 
signal 
MetPheHisGlnValArgArgValMetThrIleLeuPheLeuThrMetValIleSerTyr 
PheGlyCysMetLysAla 
Pre-3 MetGlnSerArgGluGluGluTrpCys 
Pre-3 
signal 
ValMetGlnSerArgGluGluGluTrpPheHisGlnValArgArgValMetThrIleLeu 
PheLeuThrMetValIleSerTyrPheGlyCysMetLysAla 
 
They were synthetised on aminic acrylic resin by means of a Wang Linker, a Fmoc 
Strategy and a standard DIC, HOBt protocol concerning the solid phase peptide 
synthesis. At the end of the synthesis the peptides were analysed by ES-MS 
(Figure 3.17) and HPLC (Figure 3.18) as described in 5.2.5 and 5.2.4. Results 
related only to PreBDNF1 antigen were reported. 
 
 
Figure 3.17: ES-MS analysis of PreBDNF1 peptide synthesised on aminic polymer. In the 
black rectangle the corresponding peak. 
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Figure 3.18: HPLC analysis of PreBDNF1 peptide synthesised on aminic polymer. In the 
black rectangle the corresponding peak. 
The other required antigens namely, Mature1-12 and Mature91-102 , were 
provided by Pacific Immunology. 
 
3.3.3.2 Immobilisation of PreBDNF1 on epoxy resin and first purification trials 
During the preparation of a chromatographic resin the key point is the loading of 
the molecule involved in the recognition and binding step. There is a fine 
regulation in the modulation of the loading of the resin: sometimes is not 
possible to increase the concentration of the target molecule due to a decrease 
(or a no-variation) in the purification yield because of steric hindrance that does 
not allow the recognition and capture of the molecule of interest. 
The concentration of epoxy group of the chosen matrix, is around 47μmol/g wet. 
The Sulfolink immobilisation protocol suggested a 1mg peptide as the optimal 
amount to be linked to the resin but the maximum loading achievable by the 
support was estimated around 20μmol of peptide. It corresponds to a 
concentration of 5mg of peptide/ml of resin. In order to carry out some tests to 
verify the possibility of maximising the antigen concentration by reaching the 
saturation point of the support, PreBDNF1 antigen was chosen and purification 
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columns loaded with 1mg, as stated by Sulfolink method, and 5mg of peptide 
were prepared.  
At the end of the immobilisation, a blocking step 227,228,229 with β-
mercaptoethanol to avoid non desired binding of immunoglobulins to a non-
reacted epoxy group during the purification step were done. (Paragraph 5.4.4.4) 
O
SH
S
OH
OH
OH
+
 
Figure 3.19: Blocking with β-mercaptoethanol. 
The whole IgG fraction of Pacific Immunology 1347 serum was purified by 
employing the new nProtein-A agarose support (paragraph 3.3.2) in order to 
ensure a high standard of purity of the final sample. The total IgGs were used to 
carry out the specific PreBDNF1 antibodies purification on 1 and 5mg column 
(paragraph 5.4.5.2). At the end flow-through, washes and purified fractions of 
only 1mg column were assayed for the specificity by dot-blot as described in 
paragraph 5.4.3.1. 
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Figure 3.20:Dot-blot of Pacific Immunology 1347 serum purified by 1mg antigen column. 
With regard to dot-blot membrane of Figure 3.20, in the total IgG fraction a high 
concentration of immunoglobulins was observed. In fact the signal reached the 
saturation and, as expected, the serum is positive towards all antigens. The flow-
through, presented a residual positivity towards all antigens; this shows that not 
all the PreBDNF1 IgG were linked by the column. This should be due to a lower 
concentration of antigen on the column (1mg), compared to the abundance of 
specific IgG present in the serum. The concentration of peptide stated in the 
Sulfolink protocol was considerably less than that required for an effective 
purification process. The pre-elution wash gave a clearly visible response to the 
PreBDNF1 and this can be justified either with the excess of IgG, previously 
discussed, and the fact that polyclonal immunoglobulins bind with different 
affinities and strengths to the antigen. Those which interact weakly with the 
target may break off during the washing step. The final wash showed a very light 
positivity: probably not all IgG were detached from the support during the 
elution and, during the wash step, where an elution buffer residue was still 
present, a mild pseudo elution occurred. 
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Elution samples were tested by dot-blot at different dilutions. In Figure 3.21 it is 
possible to observe that no substantial differences between the 1:50 and the 
1:250 dilution in all the samples were present. A difference was detected in 
elution 3, were the signal was below the saturation point with regard to all the 
antigens: this indicates a lower concentration of specific IgG, as expected 
considering that this is the last elution step. The most important observation is 
the absence of recognition of BDNF which indicates the specificity of the purified 
IgG (it has to be underlined that ProTotal contains the Pre- region). 
 
Figure 3.21: Dot-blot of Elution Fraction at different concentrations. Pacific Immunology 
1347 serum was purified by 1mg antigen column. 
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Considering the first results of 1mg PreBDNF1 purification column, a further 
purification was performed with the 5mg column. The maximum amount 
possible to be loaded onto the resin was 5mg. For this reason an SDS-Page and a 
UV280nm absorbance measurement, in order to verify and compare purity and an 
eventual concentration increase of specific IgG in the elution, were carried out 
(Paragraph 5.4.3.2). 
The results show that there was twice the increase in the quantity of purified 
antibody in the 5mg column elution fraction compared to the 1mg column (Table 
3.10). 
Table 3.10: IgG purification by 1mg and 5mg PreBDNF1 columns: elution fraction 
quantification. 
Column antigen loading Total IgG loaded Specific IgG purified 
 mg mg 
1mg 
0.586 
0.234 
5mg 0.460 
 
Moreover the final eluate keeps a high purity standard with no albumin 
contamination (Bands related to BSA are not visible, Figure 3.22). 
 
Figure 3.22: SDS-Page of the elution fraction after the purification of PreBDNF1 with 1mg 
and 5mg antigen columns. 
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Therefore, the other purification columns for anti PreBDNF2, PreBDNF3, 
Mature1-12 and Mature91-102 antibodies were prepared with a 5mg of peptide 
per ml of resin. 
 
3.3.4 Purification of Pre2, Pre3, Mature1-12 and Mature91-102 
The other specific IgG were purified by using the method described in the 
previous paragraph and in section 5.4.5.2. All the eluted fractions were tested 
for purity with SDS-Page (5.4.3.2) and recovery by UV280nm absorbance as well as 
PreBDNF1. All the samples showed high purity (SDS-Pages not reported). The 
elution fraction concentrations are listed in the table below: 
Table 3.11: Concentration of the eluted IgG samples of anti Pre2, Pre3, Mature1-12and 
Mature91-102. 
Antigen Specific IgG purified 
 Mg 
PreBDNF1 0.460 
PreBDNF2 0.032 
PreBDNF3 0.277 
Mature1-12 0.818 
Mature91-102 0.337 
 
The different concentrations of samples could be related to a different capacity 
to recognise and bind the antigen of a polyclonal population of antibodies66. 
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3.4 Localisation of the different isoform of BDNF 
The aim of the purification of the different BDNF antibodies was their 
applicability for biological tests in order to localise them in the neuronal cell. 
Once purified, the antibodies PreBDNF1, PreBDNF2, PreBDNF3, Mature1-12 and 
Mature91-102 were tested for their capability of recognising and binding the 
specific sequences in vivo. Immunofluorescence assays on cultures of rat 
hippocampi in the second post-natal day (P2) were performed as reported in 
section 5.4.3.8. Immunofluorescence assays on cultures of rat hippocampi in the 
second post-natal day (P2) were performed. The culture was tested after 24h 
incubation with 40mM bicuculline and in control conditions (no bicuculline 
added) as described in paragraph 5.4.3.7. The bicuculline is a GABA receptor 
antagonist and it increases the excitatory synaptic activity. This stimulation 
increases the quantity of phosphorylated eukaryotic elongation factor 2 which 
controls the transit of mRNA through the ribosome. The eEF2 phosphorylation 
by eEF2 Kinase slows the protein translation and elongation but increases the 
translation of some mRNA localised in dendrites. The dendritic synthesis of BDNF 
protein is dependent on eEF2 phosphorylation: BDNF synthesis is increased in 
neurons over-expressing eEF2K171. 
 
3.4.1 In Neuronal Cell 
The neurons were stained simultaneously with anti-BDNF antibodies (directed 
towards different portions of BDNF protein) and with cytoskeleton microtubule-
associated protein-2 (Map2) antibodies, which mark only the body and dendrites 
of neurons. To allow the localisation of the rabbit and the anti-Map2 antibodies, 
anti-rabbit and anti-mouse secondary antibody conjugated with Fluorescein 
were added. 
Results and Discussion 
 
78 
The confocal microscope images showed, for non-treated culture (Figure 3.23), a 
main localisation of signal peptides in the somatic region of the neuron. In fact, 
this is the district where the formation of the native protein occurs. The Mature 
was detected both in somatic and dendritic portion. 
 
Figure 3.23: Immunofluorescence test of rat hippocampal neuronal cell non-treated with 
bicuculline. In blue: Map2 marker, In red: BDNF antibodies. 
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The bicuculline promoting the phosphorylation of eEF2 increases the translation 
of mRNA in dendrites171 (see 1.5.2.4): the results clearly showed a higher 
labelling for all PreBDNF isoforms and Mature form in this area. The signal 
peptides, as well as the Mature form were detected both in soma and dendrites. 
In particular anti-Mature91-102 shows a higher capacity of recognition 
compared to Mature1-12 antibodies. 
 
Figure 3.24: Immunofluorescence test of rat hippocampal neuronal cell treated with 
40mM bicuculline for 24h. In blue: Map2 marker, In red: BDNF antibodies. 
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3.4.2 In Golgi apparatus 
The Golgi complex plays a central role in the intracellular transport, processing 
and sorting of proteins in the secretory pathway. Morphological and functional 
studies have established that the Golgi complex of higher eukaryotes is 
organised into at least three contiguous but distinct regions: the cis-Golgi 
network (CGN), the Golgi stack and the trans-Golgi network (TGN)230. In these 
regions different functions are carried out: it is the entry site for proteins 
transiting from the ER into the Golgi complex, there are resident carbohydrate-
modifying enzymes for the glycosylation231,232 and it is also the site of proteolytic 
processing233.  
In order to locate the Golgi structure and analyse the BDNF distribution into the 
Golgi apparatus, antibodies directed towards GM130, a protein member of the 
Golgin family and always present in Golgi matrix234 anti-BDNF antibodies were 
used.  
The results regarding the location of the different PreBDNF forms within the 
Golgi apparatus were the same for the bicuculline-treated (Figure 3.26) and non-
treated cultures (Figure 3.25). PreBDNF1 is not localised in Golgi vesicles, but 
PreBDNF2 and PreBDNF3 are well co-localised in Golgi apparatus as well as 
Mature1-12 and Mature91-102 (Figure 3.25). This finding is unexpected because 
the sequence of PreBDNF1 is included into PreBDNF2 and PreBDNF3 signal 
peptide sequences. Nevertheless the antibody against PreBDNF1 seems to be 
exclusive for the recognition of isoform1 of the signal peptide. It could be 
hypothesised that the longer chain of signal peptide 2 and 3 may cover the 
portion relative of the Pre1 sequence.  
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Figure 3.25: Localisation of BDNF in Golgi apparatus in non-treated hippocampal culture. 
Red: Golgi stucture, Green: localisation of anti-BDNF antibodies. 
Results and Discussion 
 
82 
 
Figure 3.26: Localisation of BDNF in Golgi apparatus in bicuculline-treated hippocampal 
culture. Red: Golgi structure, Green: localisation of anti-BDNF antibodies. 
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3.5 Fundamental principles for chromatographic matrices 
optimisation: comparison on albumin binding matrices 
For the purification of native or genetically engineered proteins affinity 
chromatography is extensively used in the downstream processing. As already 
described in the introduction, affinity based methods have several advantages: 
easy, fast and selective for the capture of a target protein. Due to the peculiar 
characteristics of this type of purification, the basic principles are applicable to 
every molecule that has got an affinity ligand. For this reason, in order to learn 
the industrial approach, a comparative optimization study on different matrices 
for the purification of albumin, in collaboration with Novozymes Biopharma UK 
Ltd., was carried out. 
Novozymes Biopharma UK Ltd wanted to compare the purification effectiveness 
of different matrices for recombinant Human Albumin (rHA). Three different 
types of new matrices, Matrix A, B and C, were investigated and then compared 
to a Novozymes’ standard matrix, Matrix D. In order to best compare the 
matrices, a partial optimisation of these was required.  The effects of loading pH, 
conductivity and flow rates and different eluents on purity and yeast antigen 
(YA) clearance were investigated. In order to enable a large number of screening 
experiments in the first part of the project used Atoll 100µL spin columns packed 
with the three different matrices. Once the optimal conditions for each matrix 
were set, a comparison of the screened matrices was carried out using the AKTA 
Purifier system.  
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3.5.1 The effect of loading pH and conductivity 
3.5.1.1 Atoll Spin Column Screen #1 
Atoll spin column runs were carried out as described in section 5.5.3.1. The 
results of this first screen showed that Matrix A had a good recovery in all 
conditions tested, except for pH 9 and 1mS.cm-1. At pH 9 and 1mS.cm-1, Matrix B 
also showed a poor eluate recovery, but in general the values were lower than 
for Matrix A, except for pH 9, 20mS.cm-1. For Matrix C the best recovery was 
observed for pH 7 at both conductivity values, whilst pH 9 low conductivity also 
gave a good recovery (See Graph 3.1, Graph 3.2, Graph 3.3). 
 
Graph 3.1: Effect of loading on the recovery for Matrix A, at low (1mS.cm
-1
) and high 
(20mS.cm
-1
) conductivity across the range pH 4 to 9. 
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Graph 3.2: Effect of loading on the recovery for Matrix B, at low (1mS.cm
-1
) and high 
(20mS.cm
-1
) conductivity across the range pH 4 to 9. 
 
Graph 3.3: Effect of loading on the recovery for Matrix C, at low (1mS.cm
-1
) and high 
(20mS.cm
-1
) conductivity across the range pH 4 to 9. 
 
3.5.1.2 Atoll Spin Column Screen #2 
Based on the data from screen #1 further investigation of loading pH (between 4 
and 9 for Matrix A; 7 and 9 for Matrix C and at pH 9 for Matrix B) and 
conductivity (between 0.5mS.cm-1 and 50mS.cm-1) was undertaken. 
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For Matrix A (Graph 3.4) the best recovery was at pH 4 at conductivity values 
between 0.5 and 20mS.cm-1. Consequently, for the next experiments low 
conductivity values were chosen. 
For Matrix B at pH 9 the recovery was best between conductivity 20 and 
50mS.cm-1 (Graph 3.5). A significant decrease in the recovery was detected for 
conductivities between 5 and 10mS.cm-1. Consequently, for further experiments 
high conductivity was chosen. 
For Matrix C the highest recovery was at pH 9 with conductivities between 
5mS.cm-1 and 20mS.cm-1 (Graph 3.6), for the other conductivity and pH values 
the recovery decreased significantly. However, the highest values were obtained 
with 3 new columns that were used in order to fulfil the entire range of 
experimental condition required in this test. At the end of the screen #1, Matrix 
C columns had been sanitized with 0.5M sodium hydroxide. A further 
investigation, carried out at pH 7, conductivity 1mS.cm-1, with 2 columns used 
during screen #1, 2 from both screen #1 and #2 and 2 new columns that had not 
seen NaOH, demonstrated that this sanitization step was not compatible with 
the matrix (Graph 3.7). Due to these results it was decided that NaOH would not 
be used for the Matrix C and alternative cleaning and storage solutions would be 
used (20% ethanol). Although this is fine for small scale work this would cause 
issues for larger scale processes. 
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Graph 3.4: Effect of loading for Matrix A across 0.5mS.cm
-1
 to 50mS.cm
-1
 conductivity, 
between pH 4 and 9. 
 
 
Graph 3.5: Effect of loading for Matrix B across 5mS.cm
-1
 to 50mS.cm
-1
 conductivity, pH 9. 
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Graph 3.6: Effect of loading for Matrix C across 0.5mS.cm
-1
 to 50mS.cm
-1
 conductivity, 
between pH 7 and 9. 
 
 
Graph 3.7: Trial for confirming the incompatibility of Matrix C with NaOH. 
 
3.5.1.3 Atoll spin Column Screen with frozen cell culture supernatant #1 
The second part of the screening on spin columns was oriented towards the 
identification of the most suitable load condition for frozen cell culture 
supernatant as the behaviour of a pure protein during chromatography, 
compared to a mixture as supernatant, can be different. This is due to the 
interactions of the other proteins and contaminants present in the mixture with 
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the purification support, but the use of purified protein is useful to quickly 
eliminate parts of the design space that definitely do not work. In this 
investigation a pH range across 4 to 7 at conductivity 2 and 10mS.cm-1 for Matrix 
A and pH from 4 to 9 at conductivity 20mS.cm-1 for Matrix B were tested. The 
results were evaluated in terms of recovery and yeast antigen clearance. 
For Matrix C (Graph 3.10) a design of experiments was used to investigate a 
broad set of conditions in a small number of experiments.  
For Matrix A, generally good recoveries were registered across all pH and 
conductivity ranges.  The highest recovery was at pH 5, conductivity 10mS.cm-1, 
and the lowest at pH 7 for both conductivities. The optimal conditions were pH 
6, conductivity 2mS.cm-1 as they gave a good recovery and the best clearance of 
yeast antigen. (Graph 3.8) 
For Matrix B, pH 5 gave the highest recovery but pH 8 was also chosen for 
further investigation due to the high value of yeast antigen clearance (Graph 
3.9). 
For Matrix C investigations DesignExpert software was used to determine the 
optimum loading conditions based on the results of the screen (Graph 3.10). 
Based on the output from the software it was found that the best condition was 
pH 6, conductivity 10mS.cm-1. 
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Graph 3.8: Supernatant Spin Column#1. Effect of loading Matrix A across 2mS.cm
-1
 to 
10mS.cm
-1
 conductivity, between pH 4 and 7. 
 
 
Graph 3.9: Supernatant Spin Column#1. Effect of loading Matrix B at 20mS.cm
-1
 
conductivity, between pH 4 and 9. 
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Graph 3.10: Supernatant Spin Column#1. Effect of loading Matrix C across 0.5mS.cm
-1
 to 
20mS.cm
-1
 conductivity, between pH 5 and 9. 
 
3.5.2 The effect of elution buffer 
3.5.2.1 Atoll spin Column Screen with frozen cell culture supernatant #2 
After the supernatant screen#1 the load conditions for all the matrices were set. 
However, as there was limited knowledge of Matrix C and the only eluant tested 
was that from the manufacturer it was decided to investigate different elution 
conditions. 
The standard elution at pH 8.5 and 100mM octanoate gave the lowest recovery 
whereas good recovery values were detected for pH 6.5 and 7.4.  
Glycine buffer gave a good recovery and the highest HCP clearance but it was 
not considered as the elution for rHA due to the low pH as this can result in 
aggregation and protein damage. The standard buffer at pH 7.4 was chosen and 
it had a good recovery and a high yeast antigen clearance (Graph 3.11). 
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Graph 3.11: Effect of elution condition for Matrix C on eluate recovery and YA clearance. 
 
3.5.3 AKTA purifier methods 
Once the best loading and elution conditions were set from screening with Atoll 
columns, scale-up to standard laboratory columns was possible. 
3.5.3.1 Breakthrough Curves  
For investigating the load capacity of the column, a chromatography run to 
determine the breakthrough was done, as detailed in section 5.5.5.1, with the 
final capacity for each matrix calculated at 10% breakthrough. 
For Matrix B the highest capacities were at pH 5, 20mS.cm-1, with pH 8 capacities 
much lower. The difference in these capacities was surprising based on previous 
results.  In order to investigate this, a breakthrough curve using purified rHA was 
also undertaken at the 2 conditions. For this it was found that the higher 
capacity was at pH 8. This suggests that although the binding maybe better at 
higher pHs, the selectivity is worse. Consequently, at the higher pH using culture 
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supernatant the binding sites are being saturated by contaminants. Flow rate did 
have some effect at pH 5 with a higher capacity at a low flow rate.  However, to 
maximise throughput it was decided that the optimum conditions would be pH 
5, 20mS.cm-1 at the highest flow rates. 
For Matrix A the capacities at pH 6, 2mS.cm-1 were the highest (although the 
profile was poor with no sharp upturn, data not shown). However, it was 
considered that due to the large dilution required to achieve the low 
conductivity this was non-optimal from an overall productivity perspective. 
Although at lab scale this is a valid assessment, using production centrifuges 
there tends to be a large dilution anyway and so this may not be such an issue. 
Nevertheless, for this comparison pH 5, 10mS.cm-1 was chosen as the optimal 
conditions. Flow rate again had an effect with the slower flow rate having a 
higher capacity, but as above it was considered that the faster flow rate would 
be chosen.  
For Matrix C the load capacities were similar at both flow rates and so the 
loading conditions were defined as pH 6, 10mS.cm-1 at high flow rate. In order to 
assess the influence of other contaminants on this capacity it was decided to use 
purified rHA for an additional break through as per Matrix B. As above the 
capacity from a purified feed stream was higher than from supernatant. 
However, the magnitude of increase was much lower than for Matrix B meaning 
the contaminants are influencing the capacity by a much lower amount and 
suggesting the matrix is more selective. 
3.5.3.2 Matrix C gradient elution 
To investigate if the elution of rHA from Matrix C was possible with a lower 
concentration of the standard eluent, a gradient elution was performed. It was 
found that the highest concentration of rHA was in the elution fraction 
correspondent to 40% of elution buffer. 
Results and Discussion 
 
94 
3.5.3.3 Matrix C purification method optimization 
During the gradient elution trial, a peak in the first elution collection sample, 
correspondent to the wash phase, was detected. In order to fully collect this 
prior to the elution, the volume of this wash was initially increased from 4 to 8 
column volumes. Run 1 confirmed that this was sufficient to ensure complete 
collection of this wash peak. 
It was found that adding 5-10% of the standard elution buffer in two different 
wash buffers resulted in a premature elution of some of the rHA. The 5% was 
considered as a potential elution buffer, but it was shown not to be sufficient to 
elute the entire albumin. 
It was found that percentages smaller than 40% of standard buffer did not 
ensure an effective elution step. A 50% of standard elution buffer was the 
minimum to ensure an effective recovery in a single step elution and was used 
directly after wash 1. 
With the chromatography conditions determined the different matrices were 
compared using 4 different feedstocks.  
3.5.4 Matrix Comparison 
Both Matrix A and Matrix B gave very similar results, except for the recovery of 
the fusion where Matrix B was better. Whether or not this is generic for other 
fusion proteins is not known and would need further testing with a broad range 
of fusion proteins. In addition, due to the low mass balances for both matrices, 
further investigation into optimal elution conditions could be useful to achieve 
the total recovery of the rHA loaded and would improve the overall 
chromatography.  
Matrix C was the second best column in terms of recovery and HCP removal with 
respect to albumin.  However, the inability to use NaOH with the matrix would 
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cause issues for its use at large scale where it will need to be sanitised and 
stored under sanitary conditions.  It was also poor at capturing the albumin 
fusion used in this study. 
Matrix D was the best matrix from these studies, it had the best binding capacity, 
generally had the highest recovery and gave by far the best HCP clearance.  It is 
also fully compatible with NaOH.  It was also best able to capture the fusion 
protein. 
All the eluted fractions had a good purity.  
The results are shown in Graph 3.12. 
 
Graph 3.12: Comparison of tested matrices.  
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4. Conclusions 
During this study a practical method for the purification of specific antibodies 
was set. 
Immobilisation of nProtein-A on an agarose based support with a non-toxic 
coupling chemistry (compared to cyanogen bromide approach), is feasible and 
gives good DBC values: results are in the same range of the commercial 
preparation of nProtein-A Sepharose 4 Fast Flow. The experimental design used 
allowed a full evaluation of each variable effect on a rational base. This analysis 
method is applicable to every study where a rational design of experiment is 
required and the analysis of the variables can be the starting point for further 
improvement of the immobilised preparation. The purification of the whole IgG 
fraction in each serum was satisfying with minimum albumin contamination 
allowing to proceed with the specific antibody purification. 
During the second phase of the study, the immobilisation of specific antigens on 
a solid support was optimised by increasing the amount of coupled antigen from 
1mg/ml to 5mg/ml, achieving  complete saturation of the resin. This variation 
leaded to a maximisation of the IgGs recovery during the chromatographic 
process, with twice the increase of the IgG concentration in the eluted fraction. 
For this reason, columns for the purification of specific antibodies, PreBDNF1, 
PreBDNF2, PreBDNF3, Mature1-12 and Mature91-102, were prepared with 5mg 
of immobilised antigen and the chromatography was carried out with a standard 
IgG purification protocol. 
The purified specific antibodies were assayed in order to verify their integrity 
and the recognition ability. Immunochemical tests showed that all the tested 
antibodies retained their peculiar characteristics allowing the mapping of 
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PreBDNF1, PreBDNF2, PreBDNF3, Mature1-12 and Mature91-102 trafficking into 
neuronal cells. But further studies are needed to better understand the transit of 
the BDNF from the ribosomes to the Golgi’s apparatus. 
Thanks to the wide range of conditions (pH, temperature, buffers, pressure), 
where acrylic polymers are applicable and the flexibility of the immobilisation 
protocol this method can be exploit for the preparation of specific column for 
the purification of a broad variety of molecules. 
The study completed at Novozymes Biopharma allowed to set the optimal 
conditions for the tested affinity matrices and also a rational comparison of 
different matrices in terms of recovery, yeast antigen clearance and final purity. 
It was demonstrated that final recovery is affected by the differences between 
the batches of supernatant. The purifications with Matrix C and Matrix D were 
effective with recovery >80% for all three batches. Matrix A and Matrix B 
showed a similar behavior around 60% for the first and the third batch and 50% 
for the second batch. 
For the fusion albumin, the recovery has been generally low, compared to the 
other batches. Matrix D was the best matrix (73%), the second was Matrix B 
(59%), Matrix C (49%) and Matrix A (38%). 
All the matrices were effective in terms of yeast antigen clearance and final 
purity. 
Thanks to the Novozymes’ project it has been possible to understand the general 
criteria for the optimisation and scale-up of the purification matrices for 
industrial application. It was also possible to acquire the principles of GMP and 
QC needed for the validation of an industrial purification platform. All these 
criteria could be applied for a further increasing of the performance and a 
scaling-up of a chromatographic resin. 
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5. Materials and Methods 
5.1 Materials 
All materials and reagents were acquired from Sigma Aldrich, except when 
indicated otherwise. 
The aminoacids, linker and reagents utilised for the peptidic synthesis were 
provided by IRIS Biotech.  
The aqueous solutions were prepared by using MilliQ water (18.2Mcm-1, MilliQ 
Plus - Millipore). 
For the synthesis of PreBDNF1, PreBDNF2 and PreBDNF3 an acrylic polymeric 
support was utilised. The amino functionalised matrix had a particle size 
between 150-300µm, a 70% average water retention and a loading capacity of 
0.69mmol/gdry. For the preparation of the antigen immobilised chromatographic 
columns also an acrylic matrix was utilised. It was an epoxy based polymer with a 
particle size of 50-150μm (average 90μm), an average density of functional 
groups of 100μmol/gdry and water retention between 65-75%. Both were 
provided by SPRIN S.p.A. 
For the preparation of nProtein-A columns a 4.6-5.0% agarose based 
bromohydrin pre-activated matrix was utilised. The polymer presented a spacer 
arm of 4-16 atoms, a particle size of 32-60µm and a degree of substitution of 
0.6-0.7mol/mol.  
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5.2 Instruments 
5.2.1 Shaking 
During the immobilisation and the batch purifications, the reaction syringes were 
agitated by Blood Tube Rotator SB1 (Stuart Scientific) at 40 rpm. For Western 
blotting, SDS-Page and Dot-blot assays a Bibby Stuart Platform Rocker STR6 
(Stuart Scientific) were utilised. In process where temperature control was 
needed, a HST 2030 thermo-shaker (Thalassia-Darai, Labtech, Trieste) was used. 
5.2.2 UV measurements 
All UV analysis were performed by Lambda 20 UV/Visibile Perkin-Elmer. 
5.2.3 Filtration 
A vacuum pump Vac V-500 (BÜCHI) connected to Vacuum Controller V-800 
(BÜCHI) was used when required.  
5.2.4 HPLC analysis 
In order to characterise the product of the solid phase synthesis, a Gilson HPLC 
system (pump 321, auto-injector 232XL, UV lamp 170) was used. UV absorbance 
was measured at =260 e 220 nm. Experiments were performed on C18 SYNERGI 
4µ Hydro-RP 80A 250 x 4.60mm column (Phenomenex). A gradient analysis was 
performed (initial conditions (0 minutes) 0% CH3CN /100% H2O – final conditions 
(40 minutes) 100% CH3CN /0% H2O) at 1ml·min
-1 flow rate. 0.05% of 
trifluoroacetic acid (TFA) was added both to organic and aqueous phases. 
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5.2.5 Mass spectrometry analysis 
The product of solid phase synthesis was characterised also by electrospray mass 
analysis performed on A API I (Perkin Elmer SCIEX). Mass/charge ratio was 
between 400 e 2400uma. Formic acid (Fluka) was added to the sample and it 
was injected at 100 µl/h.  
5.2.6 Centrifuge 
A Heraeus Biofuge Pico, for Eppendorf (0.5-2ml) and a Heraeus Multifuge 3 L-R, 
in Novozymes Biopharma UK, were used for this study. 
5.2.7 Electrophoresis and blotting apparatus 
A Bio Rad Mini-PROTEAN tetra system and a Bio Rad Trans-Blot SD semi-dry 
transfer cell connected to Pharmacia Biotech Electrophoresis Power Supply 
EPS300 were utilised to carry out the SDS-Page and the Western blotting, 
respectively. 
5.2.8 Purification runs 
Chromatography was performed on a GE Healthcare AKTA Prime purification and 
on GE Healthcare AKTA Purifier system in Novozymes Biopharma UK. Runs were 
monitored by UNICORN. 
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5.3 Buffers 
Buffers and solutions utilised during this study are listed below (any 
modifications are indicated in the protocol, if needed): 
PBS (Phosphate-buffered saline): 137mM sodium chloride (NaCl), 2.7mM 
potassium chloride (KCl), 10mM sodium phosphate dibasic (Na2HPO4), 
1.76mM potassium dihydrogen orthophosphate (KH2PO4), pH 7.4 
PBST: 0.1% (v/v) Tween-20 in PBS 
TBS (Tris-buffered saline ): 20mM Tris-Hydrochloride (Tris-HCl), 150mM sodium 
chloride (NaCl), pH 7.5 
TBST: 0.1% (v/v) Tween-20 in TBS 
Loading buffer 6x: 1M Tris-HCl, pH 6.8, 10% (w/v) sodium dodecyl sulfate (SDS), 
30% glycerol, 0.1% bromophenol blue, 9.3% (w/v) dithiothreitol (DTT) 
Running buffer (Dot-Blot): 3% Tris, 14% glycine, 1% (w/v) sodium dodecyl sulfate 
(SDS) 
Coomassie stain: 0.1% Blue Coomassie, 10% acetic acid (AcCOOH), 40% 
methanol (MeOH), 50% water 
Transfer Buffer (Western-blot): 39mM glycine, 48mM Tris, 0.037% (v/v) 
sodium dodecyl sulfate (SDS), 20% (v/v) methanol (MeOH) 
Hanks’s balanced salts solution: 4.2mM sodium bicarbonate (NaHCO3), 0.952% 
Hank’s salt powder, 12mM HEPES (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid), 33mM D-Glucose, 2mM kinurenic acid, 1mg/ml penicillin 
(Euroclone) and 1mg/ml streptomycin (Euroclone), pH 7.4 
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D-MEM: MEM with Earle’s salts (Euroclone) containing 5mM potassium chloride 
(KCl), 35mM D-glucose, 14mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethane-sulfonic acid), 0.7U/ml insulin, 360µM d-Biotine and 
1mM vit.B12, pH 7.4 
 
5.4 Methods 
5.4.1 Analytical methods 
5.4.1.1 Kaiser test 
A small amount of sample was taken and the three different solutions were 
prepared: 
Solution A: 5g of ninhydrin (2,2-Dihydroxyindane-1,3-dione) were solubilised in 
100ml of ethanol. 
Solution B: 80g of phenol were solubilised in 20ml of ethanol. 
Solution C: 2ml of KCN (0.001meq) in 100ml of diluted piperidine. 
An equal number of drops of each solution was added to the sample and the 
mixture was heated to 200°C. A violet coloration proves the presence of free 
amino groups, on the contrary a yellow coloration will be maintained.  
 
5.4.2 Computational methods 
5.4.2.1 Peptide linear structure generation 
Each initial peptide linear structure was generated by the built tool of PyMOL. 
5.4.2.2 Energy minimisation 
Energy minimisation for each structure was performed with the software 
GROMACS using the steepest descendent algorithm for 10000 steps. 
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5.4.2.3 Molecular Dynamic simulations 
MD simulation for each structure was performed with the software GROMACS in 
NVT environment, the temperature was set at 300 K and each peptide was put in 
the center of a cubic space (dimensioned for each peptide) with implicit 
solvation. 
5.4.2.4 Structure clustering 
The structure clustering was performed with the g_clusterize tool of the 
software GROMACS, the structure of each frame of the MD simulation (recorder 
every 0.002 ps) were clustered on the basis of their similarities in terms of 
RMSD, two structures were considered similar if the RMSD of their 
superimposition was less than 0.1 Å. 
5.4.2.5 Final structure superimposition 
The superimpositions of the signal sequences with their relative immune 
sequences were performed with the software PyMOL. 
 
5.4.3 Biological protocols 
5.4.3.1 Dot-blot assay 
Immunogenic peptides (Pacific Immunology) were spotted at different 
concentrations on Protran Nitrocellulose Transfer Membrane (Whatman, 
Germany) and left to dry for 30 minutes at RT prior to the immobilisation 
with 0.3% glutaraldehyde in 0.5M TBS for 30 minutes. After three TBS washes 
(2ml each), membranes were blocked for 40 minutes at RT with blocking 
solution (5% BSA in TBST). At the end the membrane was washed three times 
(2ml each) with TBST (0.05% (v/v) Tween-20 in TBS). Then, membranes were 
incubated 1 hour at RT (or overnight at 4°C) with the correspondent antisera 
diluted 1:100 in BSA/TBST solution (0.1% BSA, 0.05% (v/v) Tween-20 in TBS), 
washed three times with TBST and incubated for another hour at RT with the 
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secondary antibody, polyclonal goat anti-rabbit IgG AP conjugated (Dako), 
diluted 1:1500. After another set of washes in TBST, membranes were 
developed with NBT/BCIP solution. 
5.4.3.2 SDS-Page electrophoresis 
Proteins were separated by electrophoresis on 12% sodium dodecyl sulfate-
polyacrylamide gels at 20mAmp for about 90 minutes. 
Running gel 12% acrylamide, 10ml: 2ml of 8% acrylamide (30%acrylamide + 
0.8%bisacrylamide), 1.25ml of 1.5M Tris-HCl, pH 8.8, 50µL of 0.1% (w/v) SDS, 
50µL of 0.1% (w/v) ammonium persulfate, 1.7ml of water, 2.5µL of Temed. 
Stacking gel 3.9% acrylamide,5ml: 390µL of 8% acrylamide (30%acrylamide + 
0.8%bisacrylamide), 378µL of 1M Tris-HCl, pH 6.8, 30µL of 0.1% (w/v) SDS, 30µL 
of 0.1% (w/v) ammonium persulfate, 2.2ml of water, 3µL Temed. 
Loading buffer 6x was added to samples and the separation was performed in 
the running buffer. After transfer, Coomassie stain was applied or, if a further 
Western blotting was needed, Ponceau S (Alfa Wassermann), a reversible stain, 
was utilised to check transfer efficiency and homogenous loading. 
5.4.3.3 Western blotting 
Samples were separated by electrophoresis as described in 5.4.3.2 and 
transferred onto nitrocellulose membranes (Protran Nitrocellulose Transfer 
Membrane, Whatman) in transfer buffer at 100mA for 45 minutes. Non-
specific binding was avoided by incubating the membrane at RT with a solution 
containing 2% non-fat milk in PBST for 1h. PBST was used in the washing steps 
and 0.5% BSA in PBST to dilute the primary antibody, removing unbound 
reagents and reducing background. The blocked membrane was probed 
overnight at 4°C with the appropriate primary antibody. After 3 washes of 5min 
each, the respective horseradish peroxidase (HRP) conjugated antibodies were 
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incubated for 90 minutes. The membrane was washed 3x for 5min and at the 
end with PBS. All the passages were performed in agitation and at RT, except 
when referred otherwise. The immunoreactive bands were detected according 
to the manufacturer’s Enhanced ChemiLuminescence (Amersham) protocol, 
using the X-ray films (Kodak). 
5.4.3.4 Animal treatments  
All the procedures involving animals and their care were made according to both 
European Community (European Community Council Directive 86/609, Oja L 358, 
1, December 12, 1987; National Institute of Health Guide for the Care and Use of 
Laboratory Animals, US National Research Council, 1996) and Italian national 
laws (Decreto legge N116, Gazzetta Ufficiale, supplemento 40, 18-2-1992). All 
efforts were made to minimise both animal suffering and required animal 
number per experiment. The animals were maintained ad libidum at standard 
conditions: 22ºC (+/- 1ºC), relative humidity of 50%, and a 12h cycle of 
light/dark. 
5.4.3.5 Antibodies production 
A double strategy based on the home made production (Stabulario – Università 
degli Studi di Trieste) and on the externalisation (Pacific Immunology, USA) of 
the entire process was adopted. 
The protocol for antibodies production of Pacific Immunology is property of the 
company and it was not revealed.  
For the home made production, antigenic peptides were conjugated with 
Keyhole Limpet Hemocyanin (KLH), a carrier-protein that increases peptides 
antigenicity. 6mg of lyophilised KLH were dissolved in170μl of 0.1M borate 
buffer, pH 10 and mixed in agitation with 2mg of peptide previously dissolved in 
50μl of borate buffer. 80μl of 0.3% glutaraldehyde in borate buffer were added 
drop by drop and the solution was left 1 hour at RT. Subsequently, there were 
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added 50μl of glycine and the solution was incubated another hour at RT. Finally, 
PBS was added up to 2ml and the solution was dialysed overnight at 4°C.  
After conjugation, 200μg of immunogenic peptide were mixed in 1ml of 
physiological solution with Freund’s adjuvant and injected intramuscular in New 
Zeeland White Rabbits after local anesthetisation with lidocaine. Collection of 
iperimmune serum was obtained from posterior marginal vein of rabbit’s ear. 
We collected 20ml of iperimmune serum for the first bleed and a maximum of 
50ml for the following bleeds. After the tenth bleed, rabbits were 
exsanguinated obtaining a final bleed of about 100ml. 
5.4.3.6 Hippocampal neuron culture 
Primary hippocampal cell cultures were made from Sprague-Dawley rats, 
according to Malgaroli and Tsien method (1992) with slight modifications 
(indicated by Tongiorgi235). Hippocampi from 1 to 2 day old (P1-P2) pups were 
dissected and kept in cold Hanks’s balanced salts solution. The dissected tissue 
was then digested with 500µL of 0.25% Trypsin for 8min at 37°C. Digestion was 
blocked with 5ml of D-MEM further supplemented with penicillin, streptomycin 
1mg/ml (Euroclone), L-glutamine 2mM (Invitrogen) and 10% of heat inactivated 
Fetal Bovine Serum (H.I. FBS, Gibco), being the dissected tissue centrifuged at 
800rpm for 5min at RT. The pellet was re-suspended in 5ml of D-MEM+10% H.I. 
FBS. To isolate single cells, the re-suspended pellet was mechanically dissociated 
and slowly filtered by a sterile 40-70µm pore diameter strainer (Sarstedt), thus 
removing impurities and cellular debris. Finally, cell suspension was plated at 
120-150000 cells/well density onto 24-well plates (Sarstedt) containing 12mm2 
coverslips (Sacco) for immunofluorescence experiments, previously pre-coated 
with poly-L-ornithyne 100µg/ml for 20min, rinsed once with PBS and treated 
with 2% MatrigelTM (BD Biosciences, diluted 1:50 in Hank’s solution). Cell plate 
was placed at 37°C in a 5% CO2-humified incubator. After 1 hour, medium was 
                                                          
235
 Tongiorgi, Righi, Cattaneo; J Neurosci, 1997, 17, 24: 9492 
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replaced with fresh NeurobasalTM Medium (Gibco) supplemented with 2% B-27 
supplement (Invitrogen) and 1mM L-glutamine. After 2 days change the medium 
with fresh Neurobasal-B27-(L)Glut supplemented with 5.0µM cytosine b-D-
arabinofuranoside (ARA-C) to avoid glial cells proliferation. Cells were 
maintained in vitro for 6 or 9 days (6 DIV - 9 DIV) at 37°C in a 5% CO2-humified 
incubator and the medium was changed every 4-5 days. 
5.4.3.7 Cell treatment 
9 or 6 DIV hippocampal neurons were treated for 24 hours with a 40µM 
bicuculline concentration in neurobasal medium. Control condition cells were 
left in neurobasal medium only. 
5.4.3.8 Immunofluorescence on hippocampal neurons  
After treatment, coverslips containing hippocampal neurons were washed in PBS 
and fixated in a 2% paraformaldehyde (PFA) solution for 15min. After 6x rinse 
with PBS, cells were permeabilised with a 0.4% Triton in PBS solution for 15min 
and blocked with blocking solution (2% BSA in 0.1% Triton/PBS solution) for 
20min. The appropriate primary antibodies were diluted in blocking solution and 
incubated overnight at 4°C: rabbit anti-PreBDNF1 1:30, rabbit anti-PreBDNF2 1:5, 
rabbit anti-PreBDNF3 1:10, rabbit anti-Mature1-12 1:30, rabbit anti-Mature91-
102 1:10, mouse anti-BDNF 1:20, chicken anti-ProBDNF (Chemicon) 1:200, rabbit 
anti-Map2 1:200 (Santacruz), mouse anti-Map2 1:200, goat anti-Map2 1:50 
(Santacruz), mouse anti-Gm130 1:150 (Transduction Laboratories). After a 6x 
rinse in PBST (0.1% Triton in PBS solution), the respective Alexa Fluor conjugates 
(all diluted 1:200 in 1%BSA in PBST) were incubated for 2h at RT: goat anti-rabbit 
A488 (Invitrogen), donkey anti-rabbit A568 (Invitrogen), goat anti-rabbit A647, 
goat anti-mouse A488 (Invitrogen), goat anti-mouse A568 (Invitrogen), goat anti-
chicken A488 (Invitrogen), donkey anti-goat A568 (Invitrogen). Finally, coverslips 
were washed 6x in PBST, 6x in water and mounted on slides using a fluorescence 
anti-fade mountant containing Mowiol® 40-88. 
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5.4.3.9 Immunofluorescence data acquisition and analysis 
Coverslips were evaluated with a Nikon C1si confocal microscope, containing 
457,477, 488, 514, argon laser lines and 561 or 640 nm diode lasers. Light was 
delivered to the sample with an 80/20 reflector. The system was operated with a 
pinhole size of one Airy disk (30nm). Images were acquired by sequential laser 
scanning in order to avoid a cross-talking among different channels. Electronic 
zoom was kept at minimum values for measurements to reduce potential 
bleaching. 60X Plan Apo objective was used, collecting series of optical images at 
0.25μm z resolution step size. The corresponding voxel size of 60X images was 
80x80x250 nm (X×Y×Z). Images were processed for z-projection by using ImageJ 
(NIH, Bethesda, USA).  
All the neuron images on this thesis were captured by a Nikon C1si confocal 
microscope (60X oil immersion), a work done by Dr. Gabriele Baj and Andrea 
Colliva. 
Confocal images were processed by the ImageJ Z Project tool. All the illustrations 
were made in Adobe Photoshop CS6 (Adobe Systems). 
 
5.4.4 Immobilisation protocols 
5.4.4.1 Immobilisation of nProtein-A on agarose beads 
The immobilisation variables chosen during the Design of Experiment were set as 
stated in3.3.1.2.  
For each immobilisation sample an amount of 3ml of matrix were used with a 
resin/buffer ratio of 1/2 (v/v). During washes and immobilisation process the 
syringe (Isolute) was stirred in blood rotator and solutions were removed from 
the resin by vacuum pump for 2 min at 860 mBar. 
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An average of 6ml of resin slurry was added into the syringe and the storage 
solution was removed, reaching a volume of 3ml of resin. The polymer was 
washed 2x with distilled water and equilibrated with the immobilisation buffer 
until reaching the correct immobilisation pH. At the end of the equilibration step 
the resin was dried. The immobilisation solution was prepared, it was added to 
the resin and the reaction was carried out according to the conditions stated by 
the experimental plan. To reduce the amount of salts in the immobilised 
preparation, a pool of washing with decreasing molarity buffers, was performed 
at the end of the reaction.  
In order to evaluate the amount of bounded protein, supernatant and wash 
were recovered and tested for the protein concentration by Pierce assay. 
5.4.4.2 Blocking of remaining active groups on the agarose support 
A 1M ethanolamine solution, adjusted to pH 8.5 with hydrochloric acid 37%, was 
added to the coupled gel. The reaction was carried out for 16 hours at RT. At the 
end of the reaction the supernatant was recovered and the resin was washed 6x 
with distilled water to remove the ethanolamine.  
A resin/buffer ratio of 1/2 (v/v) was used and during the reaction the syringe was 
stirred in the blood rotator. Solutions were removed from the resin by vacuum 
pump for 2 min at 860 mBar. 
5.4.4.3 Antigen immobilisation on epoxy support  
For each immobilisation a sample amount of 1.1gwet of resin was weighted in a 
6ml reaction syringe. The matrix was equilibrated with the immobilisation buffer 
(50mM Buffer phosphate, pH 6.5). 1mg of antigen was dissolved in 3.3ml of 
immobilisation buffer and the solution was added to the support. The reaction 
was carried out for 45 minutes at room temperature. At the end, the preparation 
was washed 2x with the immobilisation buffer (3.3ml each). 
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Immobilisation and washes were performed in blood rotator with a resin/buffer 
ratio of 1/3 (w/v). Solutions were removed from the resin by vacuum pump for 2 
min at 860 mBar. In order to verify the completion of the reaction, supernatant 
was recovered and tested by Kaiser test. 
5.4.4.4 Blocking of remaining epoxy groups on the acrylic support 
A 1.5eq of β-mercaptoethanol (Fluka) were added to a 50mM phosphate buffer, 
pH 6.5. This solution was poured into the reaction syringe with the antigen 
immobilised polymer (resin/buffer ratio of 1/3 (w/v)) and the reaction was 
carried out overnight at 37°C in blood rotator. At the end of the reaction the 
solution was removed from the resin by vacuum pump for 2 min at 860 mBar 
and the resin was washed with 50ml of MilliQ water and 2x with phosphate 
buffer. 
 
5.4.5 Purification protocols 
5.4.5.1 Total IgGs purification by means of nProtein-A 
1ml of slurry of nProtein-A was added to the binding buffer (0.1M sodium 
phosphate, pH 7) and packed by gravity into a 10ml Poly-prep column. Column 
was equilibrated with 5ml of binding buffer, 5ml of elution buffer (0.1M glycine, 
pH 3) and finally with 10ml of binding buffer. 5ml of serum were prepared by 
diluting 1:1 (v/v) with binding buffer and filtering (Whatman 0.45µm) and it was 
loaded into the column. Flow-through was recovered by gravity and the column 
was washed with 10ml of binding buffer. IgGs were eluted with 5ml of elution 
buffer (0.1M Glycine, pH 3) and recovered in 5 Eppendorf tubes filled with 150µL 
of neutralisation buffer (1M Tris-HCl, pH 9). At the end the column was 
regenerated with 5ml of binding buffer and stored at 4°C in 20% ethanol 
solution. 
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5.4.5.2 Purification of specific anti-BDNF IgGs  
1.0g of immobilised resin was equilibrated with 3ml of binding buffer (0.1M 
sodium phosphate, pH 7) for 15 minutes in the blood rotator. The total IgGs 
(previously purified by means nProtein-A) were diluted 1:1 in binding buffer and 
1ml of the diluted sample was loaded into the column. The capture step was 
performed for 15 minutes in the blood rotator. Flow-through was recovered by 
gravity and the column was washed 3x (1ml each) with binding buffer. Specific 
IgGs were eluted in 3 steps (1ml each) with elution buffer (0.1M Glycine, pH 3) 
and recovered in Eppendorf tubes filled with 70µL of neutralisation buffer (1M 
Tris-HCl, pH 9). At the end, the column was regenerated with 6ml of binding 
buffer and stored at 4°C. 
5.4.5.3 DBC measurement 
An Omnifit chromatographic column (i.d. 6.6mm) was packed with nProtein-A 
resin to a 60mm bed height. Two different flow rates (0.5ml/min and 1.7ml/min) 
were applied.  
The column was equilibrated with 6ml of binding buffer (0.1M sodium 
phosphate, pH 7) prior to load the sample. An IgG excess, calculated from the 
theoretical binding capacity of the column, was applied. Polyclonal IgG (Cell 
Sciences) sample concentrations of 2.5mg/ml and 70mg/ml were tested. A 
column wash with binding buffer was performed at the end of the loading step 
and the buffer was changed into elution buffer (0.1M glycine, pH 3) when the 
UV280nm absorbance achieved 0.2AU. At the end of the elution, the column was 
re-equilibrated with at least 10column volumes (cv) of binding buffer and it was 
stored in a 20% ethanol solution. 
During the entire chromatography the UV absorbance at ʎ=280nm was 
monitored. Flow-through, wash and elution fractions were collected and assayed 
for IgG concentration by UV280nm absorbance.   
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5.5 Novozymes study protocols 
5.5.1 Analytical methods 
5.5.1.1 rHA monomer concentration by GP.HPLC 
GP.HPLC analysis was performed according to BP 097_04. 
5.5.1.2 Purity by Caliper GXII 
Purity analysis was performed according to BP 234_01. 
5.5.1.3 Yeast antigen concentration 
Supernatant and eluate yeast antigen samples were analysed by SPT ELISA 
according to BP 083_02.  
 
5.5.2 Atoll Spin column screen 
To allow a large number of experiments, the preliminary screen was performed 
with Atoll 5mm dia. x 5mm bed height centrifugally driven MediaScout® 
MiniColumns containing 100µL of Matrix A, B or C. Purified rHA and frozen 
culture supernatant were used as feedstock. All chromatographic steps were 
performed centrifugally using a Heraeus Multifuge 3 L-R as follows: 
Table 5.1: Testing conditions of Atoll Sprin Columns 
Equilibration 2 x 250µL at 200-250rpm for 3 minutes 
Loading 5 x 200µL at 250-300rpm for 3 minutes 
Wash 1 2 x 250µL at 200-250rpm for 3 minutes 
Elution 3 x 200µL at 200-250rpm for 3 minutes 
Clean 2 x 250µL at 200-250rpm for 3 minutes 
Storage 2 x 200µL at 300rpm for 3 minutes 
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Spin columns were equilibrated with 5 column volumes of the buffer 
corresponding to the conditions used for loading and eluted with 6 column 
volumes of the appropriate buffer. During the trials with purified albumin, UV 
absorbance at ʎ=280nm was read to determinate the protein concentration. 
For the supernatant screen, the load material and the collected fractions (FT, 
wash and elution) were assayed for purity and concentration by Caliper GXII, rHA 
monomer by GP.HPLC and yeast antigen by ELISA. At the end of each test, eluate 
recovery, mass balance data and yeast antigen clearance were calculated. 
 
5.5.3 The effect of loading pH and conductivity 
5.5.3.1 Atoll Spin Column Screen with purified albumin 
The preliminary screen was performed using purified albumin. Equilibration 
buffers with pH between 4 and 9 were prepared. For each pH the conductivity 
was adjusted to between 0.5mS.cm-1 and 50mS.cm-1 by dilution with water or 
addition of 5M sodium chloride.  
Purified albumin was diluted with buffer of the appropriate pH and conductivity 
to give aliquots at 2mg.ml-1. The pH and the conductivity of each aliquot was 
then checked and adjusted using sodium hydroxide or 0.5M HCl for pH and 5M 
sodium chloride for the conductivity as necessary. 1ml of load material was 
applied to each column to achieve a 20mg.ml-1 matrix loading. The procedure 
was followed as described in 5.5.2. Columns were eluted with the manufacturer 
suggested buffer and known eluants. 100µL of each collected fraction (load, FT, 
elution) was transferred to a 96-well plate and assayed by reading UV 
absorbance at ʎ=280nm. 
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5.5.3.2 Atoll Spin Column Screen with frozen cell culture supernatant 
A second screen using frozen culture supernatant prepared by thawing and 
filtering (Whatman GF/D 2.7µm and Whatman1 11µm) was performed. The 
culture was assayed for rHA monomer by GP.HPLC. The loading material was 
adjusted to different pH increments with 20% acetic acid or 0.5M sodium 
hydroxide and conductivity adjusted by dilution or addition of 5M sodium 
chloride. Sufficient material was applied to each column to achieve a 20mg 
rHA.ml-1 matrix loading. All chromatographic steps, were performed as described 
in 5.5.2. Elution fractions were assayed for rHA monomer by GP.HPLC and yeast 
antigen by ELISA. 
 
5.5.4 The effect of elution buffer for Matrix C 
These screenings were performed in duplicate, following the procedure 
described in section 5.5.2. 1ml of 2mg.ml-1 load material at conductivity 
10mS.cm-1 was applied to achieve a 20mg rHA.ml-1 matrix loading. The elution 
buffers tested were the standard Matrix C buffer recommended by the 
manufacturer at different pHs, 0.1M glycine buffer, pH 3 and 20mM phosphate, 
pH 7 with 100mM octanoate. These screenings were performed with frozen 
culture supernatant on Atoll columns following the procedure described in 
section 0. The load material and collected fractions (FT, wash, elution) were 
assayed for rHA monomer by GP.HPLC and yeast antigen by SPT ELISA.  
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5.5.5 AKTA purifier methods 
A 1cm diameter column was packed with Matrix A or B. Each was packed to 
11cm bed height such that the volume of each one was 8.6ml. A 0.66cm 
diameter Omnifit column was packed with Matrix C (3.76ml). A 1.6cm diameter 
Pharmacia XK16 column was packed with Matrix D (22.1ml). The bed height of all 
columns was 11cm. Chromatography was performed on a GE Healthcare AKTA 
Purifier system. For the breakthrough curve, a culture supernatant was used. For 
the final comparative chromatography, three different rHA culture supernatants 
and one albumin fusion were used. The load material and collected fractions (FT, 
wash, elution) were assayed for rHA concentration by GP.HPLC and for purity by 
Caliper GXII and yeast antigen by ELISA where appropriate. At the end of each 
test, eluate recovery, mass balance and yeast antigen clearance data were 
calculated. 
5.5.5.1 Breakthrough Curves 
Breakthrough curves were generated for all matrices with culture supernatant 
and for Matrix C and Matrix B with purified rHA (diluted to 5mg/ml). Each 
column was equilibrated with 5 column volumes (cv) of equilibration buffer, 
washed and eluted with 4cv of appropriate buffer. During the load step, the 
flow-through of Matrix B and Matrix C, was collected in 1ml fractions, the Matrix 
A flow-through in 10ml fractions. Wash and elution were collected in 50ml 
Falcon tubes. For supernatant, the flow-through fractions of all columns were 
assayed by GP.HPLC and by Caliper GXII for Matrix B. For purified rHA the UV 
absorbance at 280nm was measured. 
5.5.5.2 Matrix C gradient elution method 
Culture supernatant was, prepared as described in Section 5.5.3.2, was adjusted 
to pH 6 and the conductivity to 10mS.cm-1. A gradient chromatography cycle run 
using a gradient of the manufacturer recommended eluent from 0% to 100% 
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over 10cv was performed. In 15ml Falcon tubes, 2.2ml of eluted fractions, flow-
through and wash were collected and assayed by GP.HPLC.  
5.5.5.3 Matrix C method optimization 
Culture supernatant prepared as described in Section 5.5.3.2, was adjusted to pH 
6 and the conductivity to 10mS.cm-1. Chromatography cycle runs using various 
step elutions of different concentrations of the manufacturer recommended 
eluent were performed. Flow-through wash and elution were collected in 50ml 
Falcon tubes and assayed by GP.HPLC. 
5.5.5.4 Matrix C final purification method 
The four different batches of culture supernatant, 3 albumin and 1 albumin 
fusion, prepared as described in Section 5.5.3.2, were adjusted to the 
appropriate load conditions for each matrix. Samples were collected and assayed 
by GP.HPLC, HCP ELISA and Caliper. 
